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Abstract 
The contamination of pharmaceuticals and their fate in the environment have 
received increasing attention in recent years due to their potential adverse effects on 
the aquatic environment. The chemical properties of pharmaceuticals that are 
produced to resist rapid metabolism in the body to ensure adequate medicinal effect, 
may be responsible for their environmental persistence. We should understand the 
occurrence, fate and effect of pharmaceuticals in sewage treatment plants (STPs) 
which is the major pollution source. 
In this study, the concentrations of pharmaceuticals (macrolides: azithromycin, 
erythromycin, roxithromycin; B-blocker: atenolol; statin: simvastatin) were 
investigated in STPs in Hong Kong, Shenzhen and Guangzhou. All selected 
pharmaceuticals were detected in the effluents. The concentrations of azithromycin 
and simvastatin were first reported in STPs in China. Azithromycin concentrations 
were the highest in sewage influents and effluents, ranging from 233 to 1489 ng/L. In 
the STPs, the removal rates of atenolol and azithromycin (30-60%) were relatively 
higher than the other three pharmaceuticals (12-45%). The pharmaceuticals were not 
effectively eliminated by the treatment processes. Their concentrations detected in 
this study may have an effect on aquatic organisms over a long period of time. 
Further, the effects of pharmaceuticals on wastewater treatment performance were 
assessed through standard tests. The tests are designed to measure the inhibition of 
growth and nitrification activity of biomass. Atenolol and simvastatin were observed 
iii 
to have no significant inhibitory effects in two tests. Azithromycin was harmful to the 
biomass growth rate at 0.001 mg/L and inhibited as high as 80% biomass growth rate 
of sludge at 10 mg/L. All three macrolides completely inhibited nitrification activity 
when their concentrations were up to 1 mg/L. Although there was no short term effect 
of pharmaceuticals on the STPs treatment profomance at present, the increasing 
consumption of these antibiotics would elevate their concentrations in STPs, thereby 
inhibiting half of nitrification capacity. 
Finally, the degradation or transformation processes of the four pharmaceuticals 
were investigated by Zahn-Wellens test under optimized condition. Atenolol was 
found to be degraded rapidly. Azithromycin had several derivatives, some of which 
were still at high concentration with potential toxic effect. Erythromycin was 
degraded slowly before Day 18 and then parent compound and its derivatives 
dramatically decreased in a short time. No degradation of roxithromycin was found in 
the whole test. 
In this study, we confirm the existence of pharmaceuticals in STPs and their effect 
on sludge. The investigation of degradation pathway provides data on the derivatives 
of these compounds during treatment process. It would help future toxicity 
































Table of contents 
Acknowledgements j 
Table of contents vii 
List of Figures ^ 
A. 




1. INTRODUCTION 1 
1 • 1 Source and Fate of Pharmaceuticals in the Environment 1 
1.2 Occurrence of Pharmaceuticals 2 
1.2.1 Wastewater 2 
1.2.2 Sewage sludge and soil 5 
1.2.3 Surface water, ground water and seawater 5 
1.2.4 Drinking water 9 
1.3 Effects on the Environment 11 
1.3.1 Antibiotic resistance 11 
1.3.2 Ecotoxicity on the aquatic organisms 14 
1.4 Removal in the Environment 19 
1.4.1 Adsorption 20 
1.4.2 Photodegradation and hydrolysis 22 
1.4.3 Biodegradation 23 
1.5 Analytical Method of Pharmaceuticals in Environmental Samples 25 
1.5.1 Solid-phase extraction 25 
vii 
1.5.2 Liquid chromatography mass spectrometry 30 
1.6 Objectives and Outline of Thesis 33 
2 OCCURRENCE AND FATE OF SELECTED PHARMCEUTICALS IN STPS 35 
2.1 Introduction 35 
2.2 Materials and Methods 35 
2.2.1 Choice of pharmaceuticals for study 36 
2.2.2 Description of sewage treatment plants (STPs) 41 
2.2.3 Experimental approach 49 
2.3 Results and Discussion 55 
2.3.1 Occurrence of azithromycin 5 5 
2.3.2 Fate of azithromycin 59 
2.3.3 Occurrence of erythromycin 63 
2.3.4 Fate of erythromycin 57 
2.3.5 Occurrence of roxithromycin 70 
2.3.6 Fate of roxithromycin 74 
2.3.7 Occurrence of atenolol 75 
2.3.8 Fate of atenolol 79 
2.3.9 Occurrence of simvastatin g 1 
2.3.10 Fate of simvastatin 34 
2.3.11 Fate of pharmaceuticals during different treatment process 85 
2.3.12 Contribution of industrial (manufacturing) plants to STPs 87 
2.3.13 Seasonal variation §7 
viii 
2.4 Summary 卯 
3 EFFECTS OF PHARMACEUTICALS ON ACTIVATED SLUDGE BACTERIA91 
3.1 Introduction g^ 
3.2 Materials and Methods 92 
3.2.1 Growth inhibition test 92 
3.2.2 Nitrification inhibition test 94 
3.3 Results and Discussion 95 
3.3.1 Growth inhibition of activated sludge bacteria 96 
3.3.2 Inhibition of nitrifying bacteria 102 
4 BIODEGRADATION PATHWAYS OF FOUR PHARMACEUTICALS 106 
4.1 Introduction ^06 
4.2 Materials and Methods 1Q7 
4.2.1 Test procedures 1Q7 
4.2.2 Detection method 108 
4.3 Results and Discussion 1Q9 
4.3.1 Degradation of atenolol 109 
4.3.2 Degradation of azithromycin 117 
4.3.3 Degradation of erythromycin 129 
4.3.4 Degradation of roxithromycin 133 
4.4 Summary ^34 
5 GENERAL CONCLUSIONS 135 
References I39 
ix 
List of Figures 
Figure Title Page 
1.1 Sources and distribution of pharmaceuticals in the environment 3 
1.2 Common procedures for SPE 27 
1.3 Chemical structure of Oasis HLB copolymer 31 
1.4 Separation of pharmaceuticals by XBridge™ CI 8 column 33 
2.1 Chemical structure of selected pharmaceuticals 42 
2 2 Flow diagram of sewage treatment process at the Stonecutters 44 
‘ Island STP 
2.3 Flow diagram of sewage treatment process at the Shatin and Tai 45 
Po STPs 
2.4 Flow diagram of Shenzhen STP 46 
2.5 Flow diagrams of Guangzhou STP- Phase I, II and III 47 
2.6 The procedure of sample extraction and analysis method 51 
2.7 Sample analyses by the apparatus FTICR MS 52 
2.8 Concentrations and removal rate of azithromycin at STPs in 55-
Stonecutters Island (a), Shatin (b), Tai Po (c), Shenzhen (d) and 57 
Guangzhou (e) from August 2009 to January 2010 
2.9 Concentrations and removal rate of erythromycin at STPs in 64-
Stonecutters Island (a), Shatin (b), Tai Po (c), Shenzhen (d) and 65 
Guangzhou (e) from August 2009 to January 2010 
2.10 Concentrations and removal rate of roxithromycin at STPs in 71-
Stonecutters Island (a), Shatin (b), Tai Po (c), Shenzhen (d) and 73 
Guangzhou (e) from August 2009 to January 2010 
2.11 Concentrations and removal rate of atenolol at STPs in 77-
Stonecutters Island (a), Shatin (b), Tai Po (c), Shenzhen (d) and 78 
Guangzhou (e) from August 2009 to January 2010 
\ 
2.12 Concentrations and removal rate of simvastatin at STPs in 82-
Stonecutters Island (a), Shatin (b), Tai Po (c), Shenzhen (cl) and 84 
Guangzhou (e) from August 2009 to January 2010 
3.1 The turbidity of biomass at a wavelength of 530 nm in the test 99-
period in different pharmaceuticals treatment with five 100 
concentration levels 
3.2 Inhibition of nitrification in five concentrations of macrolides 104 
and atenolol. Data are mean士SD of experiments (n=3) 
3.3 Inhibition of nitrification in three concentrations of simvastatin 105 
4.1 DOC elimination of atenolol in the test vessels (n=3) and 111 
corresponding DOC in the procedure (n=2) and blank control 
vessels (n=2) during the ZWT 
4.2 Mass spectrum of atenolol in positive ESI mode and proposed 112 
fragmentation pathway of atenolol derived from MS^ in FT-ICR 
mass spectrometer 
4.3 Concentration of atenolol (solid line) and its linear regression 113 
line (dashed line) at the early stage in the test vessels 
4.4 TIC of Day 0 (a) and Day 4 (b) ZWT samples 1 1 4 
4.5 Mass spectrum of the peak at a retention time t=6A min, which 116 
belonged to Product A at Day 4 sample 
4.6 Mass spectrum of peak at a retention time t=6.4 min belong to 117 
m/z 250.1431 
4.7 Concentration and elimination percentage of azithromycin 119 
(solid line) and its linear regression lines (dashed line) at the 
early and later stage in the test vessels 
4.8 Chromatograms showing the change of prominent peaks in the 122 
experimental period of Day 0 (a), Day 12(b) and Day 28(c) 
\i 
Mass spectrum of azithromycin and its fragmentation ions in 123 
positive ESI mode and proposed fragmentation pattern derived 
from MS/MS 
4.10 Course of specific masses of transformation/biodegradation 125 
products in ZWT 
4.11 Mass spectrum of P829 and proposed structure of fragmentation 126 
ion derived from MS/MS 
4.12 Mass spectrum of P793 and fragmentation ion derived from 127 
MS/MS 
4.13 Probable structures of biodegradation products and its 128-
corresponding daughter ions following LC/MS/MS analysis 129 
from DP610 
4.14 Proposed structures of derivatives of azithromycin and possible 130 
metabolic pathways in activated sludge 
4.15 MS/MS spectrum and elimination percentage of erythromycin 131 
in the test vessels 
4.16 TICs showing the change of peaks in the experimental period of 132 
Day 0 (a), Day 18(b), Day 22 (c) and Day 28(d) 
4.17 Course of specific masses of derivatives of erythromycin in 133-
ZWT, MS/MS spectrum of P720 and structure of P748 134 
4.18 Fragmentation pattern of roxithromycin in MS/MS spectrum (a) 135 
and concentration of it protonated molecular ion (m/z 837 5379) 
(b) 
xii 
List of Tables 
Title Page 
1.1 Summary of pharmaceuticals concentrations measured in tap 10-
water 11 
1.2 Toxicities of pharmaceuticals on aquatic organisms 15-19 
1.3 SPE methods for the extraction of pharmaceuticals from water 28- 30 
samples in different references 
2.1 Physical and chemical properties of selected pharmaceuticals 41 
2.2 Summary of STPs studied in Hong Kong and Guangdong 43 
Province 
2 3 Wastewater characteristics of the five STPs(Stonecutters Island 
• ⑴，Shatin(2), Tai Po(3), Shenzhen(4) and Guangzhou(5)) 49 
2.4 FTICR MS parameters, linear R^ of standard curves, method 54 
detection limits (MDL) and procedure recoveries for selected 
pharmaceuticals spiked in influent and effluent 
2.5 Total removal efficiency of five pharmaceuticals in different 90 
treatment processes 
3.1 Growth inhibition of sludge biomass by different concentration 102 
of pharmaceuticals 
4.1 Composition of ZWT medium (mg/L) 109 
4.2 Data of HPLC-FTICR-MS analysis for azithromycin and its 120-





COD Chemical oxygen demand 
DCA Des-cladinose azithromycin 
DOC Dissolved organic carbon 
EC 10 Effective concentration to 10% 
ESI Electronspray ionization source 
FTICR MS Fourier transform ion cyclotron resonance mass spectrometry 
FTICR MS/MS Fourier transform ion cyclotron resonance tandem mass 
spectrometry 
GZ Guangzhou 
HLB Hydrophilic-lipophilic balance 
IC50 50% Inhibitory concentration 
LC50 Lethal concentration to 50% 
LC-MS Liquid chromatography—mass spectrometry 
LOEC Lowest observed effect concentration 
LC50 50% Lethal concentration 
MDL Method detection limit 
N O E C NO observed effect concentration 
PCR Polymerase chain reaction 
SCI Stonecutters Island 
xiv 
S1)E Solid-phase extraction 
ST Shatin 
STP Sewage treatment plant 
TIC Total ion chromatogram 
TOC Total organic carbon 
TP Tai Po 
ZWT Zahn-Wellen test 
XV 
I. INTRODUCTION 
Pharmaceuticals are useful chemicals for curing and preventing diseases, fighting 
infection, and mitigating symptoms. Most commonly used pharmaceuticals include 
antibiotics, B-blockers, lipid regulators, steroids and related hormones, 
anti-inflammatory drugs, diuretics and cancer therapeutics. These drugs serve their 
therapeutic purpose to humans, animals and plants, but may cause adverse effects on 
the environment. Numerous studies detected low concentrations (ng/L to \xg/L) of 
pharmaceuticals in the aquatic environment (Hirsch et al., 1999; Jone et aL, 2005; 
Radjenovic et al., 2009; Miege et al., 2009; Kiimmerer et al., 2009). The investigation 
of the occurrence and forms of pharmaceuticals in the environment has received 
growing attention in recent decades. Despite the increasing number of studies 
conducted, the fate and effects of these drugs are not fully understood. 
1.1 Source and Fate of Pharmaceuticals in the Environment 
The consumption and application methods of pharmaceuticals can differ 
remarkably from region to region because of different legislative background, culture, 
normal practices and "philosophies," i.e., education of doctors, pharmacists and 
patients (Verbrugh and de Neeling, 2003; Goosens et al., 2005, Kiimmerer and 
Schuster, 2008). Pharmaceuticals are introduced into the environment through usage 
by humans and animals; inappropriate disposal of expired drugs, veterinary waste and 
aquacultural medicated feeds; manufacturing plant wastes and landfill leachate to 
sewage treatment plants (STPs); and land application of biosolids (Figure 1.1). 
The veterinary drugs are used as growth promoters or therapeutics in livestock 
production in fields, or as feed additives in fish farms (Halling-Sorensen et aL, 1998). 
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In aquaculturc, drugs used as feed additives are discharged directly into the surfacc 
water. The main source of contamination is the drugs for patients from the community. 
Pharmaceuticals after treatment are excreted as the parent compound and/or 
metabolites in urine and feces which end up in STPs. Numbers of STPs were reported 
to be poor in pharmaceutical removal (Clara et al., 2005; Gobel et al., 2007; Bhandari 
er al., 2008; Kasprzyk-Hordem et al., 2009). Pharmaceuticals are exposed to the 
surface water via the discharge of sewage effluents. Containing pharmaceuticals 
residue, biosolids and animal wastes are used for land application，and drug residues 
are dispersed in the soil. These drug residues in the manure or their metabolites may 
threaten groundwater, depending on their mobility in the soil system, and also affect 
terrestrial and aquatic organisms as a result of leaching from the fields (Diaz-Cruz et 
a/., 2003). Unused, expired or used drugs are sometimes disposed of down the drain 
in households, which end up in STPs, or as household waste which ends up on landfill 
sites, where they are dissolved and enter the leachate produced from percolating 
rainwater. 
1.2 Occurrence of Pharmaceuticals 
1.2.1 Wastewater 
Researches mainly reported the occurrence of pharmaceuticals in STP effluents 
because sewage effluents are considered as the main source of aquatic pollution 
(McArdell et al., 2003; Alexy and Kiimmerer, 2006; Mompelat et al., 2009). The 
occurrence of pharmaceuticals was first documented in treated wastewater in 1976 by 
Garrison et al. in the United States where clofibric acid which belongs to lipid 
regulator was detected in concentration ranging 0.8- 2 |ag/L (Pent et al., 2006). 
2 
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Figure 1.1 Sources and distribution of pharmaceuticals in the environment (modified 
from Halling-Sorensen et al., 1998). 
The most concerned pharmaceuticals are antibiotics in the range of low jiig/L, 
including macrolides (e.g. erythromycin, clarithromycin and roxithromycin), 
tetracyclines (e.g. oxytetracycline, chlortetracycline and tetracycline), sulfonamides 
(e.g. sulfadizine, sulfamedimethoxine and sulfamethoxazole) and quinolones (e.g. 
ciprofloxacin, norfloxacin and ofloxacin). 
Miao et al. (2004) detected STP final effluents concentrations of five sulfonamides 
(sulfadiazine, sulfamethazine, sulfamethoxazole, sulfapyridine and sulfisoxazole) up 
to 871 ng/L in five cities in Canada. In the same study, tetracyclines (doxycycline and 
tetracycline) were also detected with a maximum concentration of 977 ng/L. However, 
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the detected concentrations of tetracycline (tetracycline 3.6 jiig/L, oxytetracycline 4.2 
Mg/L, doxycycline 10.9 |.ig/L) in STP effluent in Wisconsin, United States were at 
much higher levels (Karthikeyan et al., 2006). In Maryland, antibiotics including 
triclosan, biphenylol and chlorophene were reported with concentrations ranging 100 -
250 ng/L in the effluent (Yu et al., 2006). Peng et al (2006) reported high levels of 
detected ofloxacin (5.70 jiig/L), sulfonamides (sulfadiazine 4.18 jug/L and 
sulfamethoxazole 9.46 jag/L) and chloramphenicol (1.46 jug/L) in STP effluent, 
Guangzhou, China. 
Analgesics and anti-inflammatories are also frequently presented in the effluent at 
high concentration level, especially diclofenac, ibuprofen and naproxen. The 
measured mean concentrations of wastewater effluent in Seville, Spain were 8.20, 
0.84 and 2.10 jug/L for ibuprofen, ketoprofen and naproxen, respectively (Santos et al., 
2009) while that of carbamazepine was 0.56 jag/L. Yu et al (2006) detected lower 
concentration diclofenac, ibuprofen, ketoprofen and naproxen between 250 and 350 
ng/L in Maryland, United States. Similar ibuprofen and naproxen contamination 
concentration was found in south of France, except ketoprofen at 1081 ng/L (Rabiet et 
(3/., 2006). Acetaminophen which belongs to analgesic was also present in New York 
STP effluent at 0.86 jig/L (Benotti et al., 2007). Caffeine was detected in many 
regions at high concentrations up to 20 |ig/L in the effluents (Rabiet et al,, 2006; 
Benotti et al., 2007; Santos et al., 2009). 
Benotti et al. (2007) reported high concentrations of other pharmaceuticals in New 
York STP effluent, like B-blocker salbutamol (8.1 jug/L), antidepressant fluoxetine 
(0.56 )ag/L) and antidiabetic metformin (11 |Lig/L). In South Korean effluents, 
4 
ioproinidc (contrast medium) was found at concentrations as high as 4.03 |ag/L (Kim 
c t 2 0 0 7 ) . 
1.2.2 Sewage sludge and soil 
In contrast to water samples, reliable analytical methods for soil are relatively few 
so that the occurrences of pharmaceuticals have not been well investigated. In the 
wastewater treatment process, pharmaceuticals and their metabolites can move into 
the solid phase according to their hydrophobicity, and this will significantly reduce the 
biodegradability of the organic compounds (Kelsey et al., 1997; Nam et al., 1998). 
Therefore, pharmaceuticals in sediment, biosolid and soil are more stable. 
Seventy-two pharmaceuticals were determined in 110 biosolid samples collected by 
the U.S. Environmental Protection Agency (EPA) in 2001 National Sewage Sludge 
Survey (McClellan et al, 2010). Thirty-eight pharmaceuticals were detected at 
concentrations ranging from the low jug/kg to mg/kg range. The two most abundant 
contaminants were two antibiotics, triclocarban and triclosan, with mean 
concentrations of 36 and 12.6 mg/kg, respectively. 
Application of sewage sludge to soils may be a route for pharmaceuticals to enter 
the terrestrial environment. In Italy, sewage sludge samples contained 2090 ng/kg 
ciprofloxacin, 3408 ng/kg L floxacin/ofloxacin, 156 ng/kg clarithromycin, 185 ng/kg 
erythromycin and 658 ng/kg spiramycin (Zuccato et aL, 2010). Ying et al. (2007) 
investigated triclosan concentrations which ranged from 0.09 to 16.79 mg/kg on dry 
weight basis with a median concentration of 2.32 mg/kg in 19 STPs biosolid in 
Australia. The persistent of tetracycline in soil fertilized with liquid manure was 
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proved by residue concentration was up to 86.2 - 198.7 jag/kg in Germany (Hamschcr 
c'/ ill., 2002). When untreated and digested sludge containing two quinolone 
antibiotics (ciprofloxacin and norfloxacin) up to 2 mg/kg of dry mass were applied to 
soil, up to 0.4 mg/kg of dry mass ciprofloxacin and norfloxacin was detected in the 
sludge-treated soil (Golet et al., 2002). Tetracycline residues in soils amended with 
liquid manure (oxytetracycline: 2683 jug/kg, chlortetracycline: 1079 jag/kg, 
tetracycline: 105 j^g/kg) had higher concentrations than sulfamides and quinolones in 
northern China (Hu et al., 2010). Besides the difference in usage, the variation in 
chemical properties of antibiotics was a major reason of their different distribution. 
Sewage effluent irrigation on land may be another source of pharmaceuticals that 
bioaccumulat in the soil. Irrigation comprises 65% of all water use worldwide. The 
growing global demands on available irrigation water increase the proportion of 
sewage effluent reused around the world (Levine et al., 2004). Researchers have 
estimated the residues of several pharmaceuticals in soil which had been irrigated for 
15 years by sewage effluents containing ibuprofen, naproxen caffeine and 
carbamazepine (Gielen et al., 2009). Carbamazepine and caffeine leached consistently 
below the top 0.9 m of soil, and greater than 300 ng/L of carbamazepine was detected 
in soil water. 
1.2.3 Surface water, ground water, and seawater 
The first documented study of surface water polluted by antibiotics was more than 
20 years ago by Watts et al. (1983) who detected 1 |ag/L macrolide, sulfonamide, and 
tetracycline in the river water samples in England. In the last few years, knowledge 
about occurrence of pharmaceuticals has increased to a large extent due to new 
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analytical tccliniqucs that are able to determine polar compounds at trace 
concentrations. 
In Korean surface waters, including several lakes and rivers, Kim et al (2007) 
detected analgesics and anti-inflammatory (naproxen, ibuprofen, diclofenac) which 
ranged 1.1-38.0 ng/L. In the rivers in northern Italy, Calamari et al (2003) detected 
maximum concentrations of macrolides (spiramycin: 74 ng/L, lincomycin: 249 ng/L), 
diuretics (ftirosemide: 255 ng/L, hydrochlorothiazide: 256 ng/L), B-blocker (atenolol: 
241 ng/L). Kolpin et al (2004) collected upstream and downstream of selected towns 
and cities in Iowa during high-, normal- and low-flow conditions to determine the 
concentration of 105 pharmaceuticals and other organic wastewater contaminants. 
Sixty-two compounds were found. The most frequently detected compounds were 
cholesterol (plant and animal sterol), caffeine (stimulant), B-sitosterol (plant sterol) 
and 1,7-dimethylxanthine (caffeine derivative). 
Three analgesics were also reported in the Pearl River in southern China. With their 
maximum detected concentrations of naproxen, ibuprofen and diclofenac reached up 
to 125, 685 and 150 ng/L, respectively (Zhao et al., 2009). But in the river in Spain, 
anti-inflammatory were detected at quite high level; Ibuprofen reached up to 2784 
ng/L, ketoprofen had maximum concentration of 991 ng/L, while naproxen was as 
high as 640 ng/L (Fernandez et al., 2010). 
In the groundwater samples from Baden-Wurttemberg, Germany, the maximum 
concentration of sotalol (560 ng/L), diclofenac (590 ng/L), contrast medium 
(iopamidol: 300 ng/L, amidotrizoic acid: 1100 ng/L), antiepileptic (carbamazepine: 
7 
%() ng/L) and sultametlioxazole (410 ng/L) (Sacher et ciL, 2001). The occurrcncc of 
pharmaceutical compounds detected in groundwater was mainly due to the direct or 
indirect impact of wastewater. The occurrence of 15 antibiotics in Seine River, France 
was documented by Tamtam et al (2008). In this case, sulfamethoxazole (up to 544 
ng/L), norfloxacin (up to 163 ng/L) and ofloxacin (55 ng/L) showed relatively high 
concentrations. 
Batt et al (2006) found groundwaters contaminated by two veterinary 
antimicrobials, sulfamethazine (ranged 76-220 ng/L) and sulfadimethoxine (ranged 
46-68 ng/L) in Idaho, United States. Their concentrations were within the range of the 
reported ECio for sulfonamides that causes considerable reduction in the number of 
soil bacteria. And temporary selective pressure on soil microorganisms could take 
place. The occurrence and distribution of sulfonamides in the groundwater 
downgradient from a landfill site in Denmark has been investigated by Holm et al. 
(1995). The concentration of sulfonamides decreased with distance from the landfill. 
At a distance of 50 m from the landfill, up to 500 |ug/L sulfonamides could be 
detected in the groundwater. 
We know little about the presence of drug residues in marine ecosystems. Minh et 
<3/. (2009) investigated the presence of 16 antibiotics in Victoria Harbour in Hong 
Kong and found cefalexin, amoxicillin, ofloxacin and erythromycin-H20 which were 
ubiquitous in sea water throughout the harbour with concentrations ranging 
0.64-76.00 ng/L. Roxithromycin and norfloxacin were also detected in Victoria 
Harbour at 4.2-30.6 ng/L (Xu et al., 2007), but sulfadiazine, sulfadimidine, 
sulfamethoxazole, amoxicillin and chloramphenicol were not detected. The difference 
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o t � t w o studies may be caused by different sampling time. Weigcl el al. (2002) 
investigated North Sea areas for the occurrence ofclofibric acid, diclofenac, ibuprofen, 
ketoprofen, propyphenazone and caffeine but only found clofibric acid and caffeine 
throughout the North Sea at concentrations of up to 1.3 and 1.1 ng/L, respectively. 
1.2.4 Drinking water 
Researchers are concerned about what level of risk may be associated with the 
presence of pharmaceuticals in drinking water impacted by wastewater. But currently, 
few papers have been published regarding the occurrence and removal of 
pharmaceuticals in drinking water treatment. Most of them are listed in Table 1.1. 
Kim et al (2007) tested the removal of pharmaceuticals by conventional drinking 
water treatment processes used in two Korean cities and found inefficient elimination 
of pharmaceuticals in the source water. In Germany, similar experiments were 
conducted to study removal efficiency of four pharmaceuticals (bezafibrate, clofibric 
acid, carbamazepine, and diclofenac) in different drinking water treatment methods 
(Temes et al., 2002). The removal effect was not significant in sand filtration under 
natural aerobic and anoxic conditions, but the removal rates were high in the 
ozonation filtration with granular activated carbon. 
In southern California, Loraine et al. (2006) detected the occurrence of ibuprofen 
(510- 1350 ng/L), ibuprofen methyl ester (4950 ng/L), and triclosan (734 ng/L) in the 
drinking water. None of these detected compounds is currently regulated in the 
drinking water. Selected pharmaceuticals were measured in the finished water of 19 
drinking water treatment plants in the United States at concentrations up to 42 ng/L, 
including atenolol, carbamazepine, phenytoin, meprobamate, triclosan and 
sultamethoxazole (Stackelberg et al., 2007; Benotti et al., 2009). 
Table 1.1 Summary of pharmaceuticals concentrations measured in tap water. 
Country, Cone 
State/City Therapeutic use Compound ^^^^^^ Refrence 
United States, Antibiotics Triclosan 734 Loraine et al, 
California NSAIDs and Ibuprofen 1350 2006 
analgesics 
United States, Antiepileptics Carbamazepine 140-258 Stackelberg, et 
New Jersey Psychostimulants Caffeine 60-119 al., 2004, 2007 
United States, Antidepressants Meprobamate 5.9 Vanderford et al., 
Nevada 2006 
Meprobamate 42 Benotti et al., 
Phenytoin 19 2009 
Antibiotics Triclosan 1.2 
Antiepileptics Carbamazepine 18 
B-blocker Atenolol 18 
Italy, Roma Antibiotics Sulfamethoxazole 80 Perret et al., 2006 
Sulfamethizole 9 
Sulfadimethoxine 11 
Italy, Lombardy Antidepressants Diazepam 23.5 Zuccato et al.. 
Lipid regulators Clofibric acid 5.3 2000 
Antibiotics Roxithromycin 18 Vulliet et al., 
Antiepileptics Carbamazepine 32 2009 
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Table 1.1— (Cont'd) “ 
Country, Crm� 
State/City Therapeutic use Compound� ； ) � • ) Refrence 
France, Solaize Hormone Levonorgestrel 10 Vulliet et al, 
Norethindrone 6.8 2009 
Testosterone 26.4 
Progesterone 10.7 
NSAIDs and Ketoprofen 7 
analgesics Ibuprofen 18 
France, Talence Antidepressants Amitryptilline 1 A Togola et al., 
Antiepileptics Carbamazepine 43.2 2008 
NSAIDs and Acetaminophen 210.1 
analgesics Ibuprofen 0.6 
Psychostimulants Caffeine 22.9 
Germany, Berlin Antiepileptics Carbamazepine 60 Heberer et al, 
Primidone 40 2004 
N S A I D S and Diclofenac 35 
analgesics Propyphenazone 240 
Netherlands, Antibiotics Sulfamethoxazole 30 Schriks et al, 
Nieuwegein Antiepileptics Carbamazepine 30 2010 
Lipid regulators Clofibric acid 140 
Finland, Turku NSAIDs and Ibuprofen 8.5 Vieno et al., 2005 
analgesics 
1.3 Effects on the Environment 
1.3.1 Antibiotic resistance 
11 
The resistance of bacteria to antibiotics have been found in water (Chee-Sanford el 
2001; Ohlsen et a!., 2003; Duong et aL, 2008; Zhang et al., 2009; Al-Ahmad et aL, 
2009; Tao et al., 2010), soil and sludge (Reinthaler et aL, 2003; Rysz et al., 2004). 
However, the emergence of antibiotic resistance is a remarkably complex process and 
its significance to the environment is not fully understood (Alanis, 2005). Kiimmerer 
(2009) addressed that the main concern is whether the input of antibiotics into the 
environment is an important source in the emergence of resistant bacteria in the 
environment. 
An investigation of the pathogenic Streptococcus pneumoniae collected from 13 
countries, 0.8% of 5015 isolates were found to be levofloxacin resistant and the 
highest resistance rates were in Hong Kong (8.0%), China (3.3%) and Spain (1.6%) 
(Critchley et al., 2002). Sewage sludge and liquid pig manure are possible sources of 
antibiotic resistant bacteria (Holzel et al., 2010). E. coli from pig manure were 
resistant to streptomycin (56.5%) and doxycycline (54.7%), while 凡 coli from sewage 
sludge were mostly resistant to spectinomycin (26.7%) and ampicillin (19.8%). 
Sewage discharge and input from other anthropogenic sources along the rivers are 
also possible sources of multiple drug resistance in Enterobacteriaceae bacterial 
isolates from sites along Pearl Rivers (Tao et al., 2010). The isolates were tested for 
susceptibility to seven antibiotics (ampicillin, chloramphenicol, ciprofloxacin, 
levofloxacin, sulphamethoxazole, tetracycline and trimethoprim). In another river in 
China，Haihe River, relatively high concentrations of sulfonamide resistance genes 
O'w/l and sul2) were detected in all the 38 collected water and sediment samples (Luo 
e广 al., 2010). Concentrations of sull and sull in sediments were 120-2000 times 
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higher than that in water which suggested that sediments are an important antibiotic 
resistance genes reservoir in the Haihe River. However, tetracycline resistance genes 
(/t^/W, tetQ, tetO, tetT, tetM，tetB, and tetS) were only detected by quantitative PGR in 
a few samples. 
In the United States, two tetracycline resistance genes telW and tetO were detected 
in treated drinking water and recycled wastewater. It indicated that there were 
potential routes for the spread of antibiotics resistance genes to humans (Pruden et al., 
2006). They are possibly transferee! from wastewater, then surface water, and to the 
drinking water distribution network. In Germany, antibiotic resistance genes vanA and 
ampC were detected in all wastewater and drinking water biofilms, but enterococci 
and Enterobacteriaceae, which are said to carry these genes originally, were never 
found in drinking water biofilms (Schwartz et al., 2003). It suggested that the 
amplified genes belong to part of the genome of viable but non-cultivable aquatic 
bacteria. In 51 drinking water points in Turkey, nearly 57% of collected organisms 
exhibited resistance to three or more antibiotics commonly used in human and 
veterinary medicine (Alpay-Karaoglu et al., 2007). 
Water distribution systems are assumed to be an important reservoir for the spread 
of antibiotic resistance to opportunistic pathogens (Xi et al., 2009). Generally, the 
levels of bacteria in source water were higher than those in tap water, but the levels of 
antibiotic-resistant bacteria were higher in tap water than in finished water. This 
phenomenon suggests that there was regrowth of bacteria in the drinking water 
distribution systems (Xi et al., 2009). 
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1.3.2 Ecotoxicity on the aquatic organisms 
On exposure to most pharmaceuticals, the lethal concentrations (LC50) range from 
high mg/L to low mg/L, while the environmental concentrations of these compounds 
are from ng/L to |ig/L. Drugs pose a low risk for acute toxicity, so the data are only 
useful when accidental discharge of these drugs happens. For chronic toxicity, there is 
a scarcity of the information on the effects of subtherapeutic drug concentrations on 
the life cycle of aquatic vertebrates and invertebrates. The organisms possess the 
receptor or use the biosynthetic pathway, with enzymes exhibiting structures nearly 
identical, or at least similar to human counterparts. 
However, some pharmaceuticals can be toxic to some organisms at environmental 
concentration. Pomati et al. (2007) found a mixture of pharmaceuticals at 
environmentally relevant concentrations (ng/L) could remarkably inhibit zebrafish 
liver cell proliferation in vitro over a 72 h exposure time. Compared to unexposed 
controls, upregulation of gene expression identifying protein kinase signalling 
pathways and DNA-repair mechanisms were detected in exposed zebrafish liver cells 
possibly because of the effects of specific pharmaceuticals. Table 1.2 lists the toxicity 
of pharmaceuticals to aquatic organism. 
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Table 1.2 Toxicities of pharmaceuticals to aquatic organisms. * 
Species Compound Toxicity (concentration/ Reference 
endpoint) 
‘ 心 彻 C l o f i b r a t e 36.6 mg/L (48 h LC50) Nunes et 
partheuogenetica 2005 
Clofibric acid 87.22 mg/L (48 h LC50) ， 
Diazepam 12.2 mg/L (48 h LC50) 
Ceriodaphnia Dexamethasone 0.05 mg/L (7 days population DellaGreca 
—ic i growth EC50) et al., 2004 
Prednisolone 0.23 mg/L (7 days population 
growth EC50) 
Propranolol 0.25 mg/L (LOEC Huggett et 
reproduction) al.，2002 
Chlorella vulgaris Oxytetracycline 6.4 mg/L (EC50) Pro et al., 
2003 ‘ 
Daphnia magna Clofibric acid 1 jug/L (increase sex ratio) Flaherty et 
al. , 2005 
Fluoxetine 36 j^g/L (increased fecundity) 
Fluoxetine 8.9 jag/L(NOEC) and 31 jag/L Pery et al., 
(LOEC) 2008 
Ibuprofen 13.4 mg/L (48 h EC50 Heckmann 
immobilisation) et al； 2007 
Metoprolol > 100 mg/L (EC50) Cleuvers, 
2003 
Propranolol 7.5 mg/L (EC50) 
Desmodesmus Metoprolol 7.3 mg/L (EC50) 
subspicatus 
Propranolol 5.8 mg/L (EC50) 
Fundulus Clofibric acid <1 mg/L (NOEC) Emblidge 
heteroclitus etaL,2006 
Gambusia Clofibrate 7.7 mg/L (96 LC50) Nunes et 
holbrooki al., 2005 
Clofibric acid 526.5 mg/L (96 h LC50) 
Diazepam 12.7 mg/L (96 LC50) 
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Table 1.2 (Cont\l) ‘ “ 
Species Compound Toxicity (concentration/ Reference 
endpoint) 
Gcwummis piilex Ibuprofen 10 ng/L mg/L (LOEC) De Lange 
et al., 2006 
Hyalella azteca Propranolol 0.1 mg/L (LOEC Huggett et 
reproduction) al., 2002 
Hydra attenuata Ibuprofen 1.65 mg/L (96 h EC50)； 1 Quinn et 
mg/L (96 h LOEC); 0.1 mg/L al., 2008 
(96 h NOEC) 
Naprofen 12.62 mg/L (96 h EC50); 5 
mg/L (96 h LOEC); 1 mg/L 
(96 h NOEC) 
Amlodipine 0.01 mg/L polyp regenerate Pascoe et 
inhibition al., 2003 
Diazepam 0.01 mg/L (polyp regenerate 
inhibition) 
Digoxin 0.01 mg/L polyp regenerate 
inhibition 
Lemna gibba Atrovastatin 26.1 jug/L (EC,o) Brain et 
al,, 2006 
Lovastatin 32.8 j^g/L (EC 10) 
Lemna minor Metoprolol >320 mg/L (EC50) Cleuvers, 
2003 ‘ 
Propranolol 114 mg/L (EC50) 
Oxytetracycline 4.92 mg/L (EC50) Pro et al., 
2003 
Sulfochlorpyri- 2.33 mg/L (EC50) 
dazine 
Microalgal Clotrimazole 500 pmol/L (reduce total Porsbring 
communities sterol content) et al., 2009 
10-100 nmol/L (reductions 
in community growth, and 
changed community pigment 
profiles) 
Oryzia latipes Ifenprodil 8.71 mg/L (96 h LC50) Kim et al., 
2009 , 
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Tabic 1.2 (Cont'd) “ “ 
补ecies Compound Toxicity (concentration/ Reference 
endpoint) 
(9/:旧.“ latipes Carbamazepine 45.87 mg/L (96 h LC50) Kim et al., 
2009 ‘ 
Clarithromycin > 100 mg/L (96 h LC50) 
Ibuprofen > 100 mg/L (96 h LC50) 
Indometacin 81.92 mg/L (96 h LC50) 
Mefenamic acid 8.04 mg/L (96 h LC50) 
Propranolol 11.40 mg/L (96 h LC50) 
Triclosan 0.6 mg/L (96 h LC50) 
Propranolol 0.5 mg/L (growth) Huggett et 
0.005 mg/L (4-week al., 2002 
hatching) 
Palaemonetes Clofibric acid <1 mg/L (NOEC) Emblidge 
Pu咖 e/a/.，2006 
Pimephales Atenolol 10 mg/L (LOEC growth) Winter et 
P^omelas al., 2008 
Potamopyrgus Fluoxetine 0.47 jug/L (NOEC) and 0.81 Nentwig, 
antipodarum jug/L (ECio) 2007 , 
0.01 mg/L (NOEC) Pery et al., 
2008 
Pseudokirchne- Azithromycin 19 jug/L (growth inhibition); Harada et 
subcapitata 5.2 jug/L (NOEC) al., 2008 
Scendesmus Diclofenac 48.1 mg/L (EC50) Schulze et 
vacuolatus a/., 2010 
Tetraselmis chuii Clofibrate 39.7 mg/L (96 h EC50) Nunes et 
al., 2005 
Clofibric acid 318.2 mg/L (96 h IC50) 
Diazepam 16.5 mg/L (96 h IC50) 
Thamncephalus Carbamazepine >100 mg/L (24 h LC50) Kim et a!., 
platyurus 2009 
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Species Compound Toxicity (concentration/ Rcfcrencc 
endpoint) 
Thcwuiccphalus Clarithromycin 94.23 mg/L (24 h LC50) Kim et al., 
platyiinis 2009 , 
Ibuprofen 19.59 mg/L (24 h LC50) 
Ifenprodil 4.43 mg/L (24 h LC50) 
Indometacin 16.14 mg/L (24 h LC50) 
Mefenamic acid 3.95 mg/L (24 h LC50) 
Propranolol 10.31 mg/L (24 h LC50) 
Thamncephalus Triclosan 0.47 mg/L (24 h LC50) Kim et al., 
platyurus 2009 ‘ 
Vibrio fischeri Flumequine 1 9 0 . 2 pig/L (EC50)； 2.29 |ag/L Backhaus 
(EC,o)； 2.64 jLig/L (NOEC) et al., 2000 
Lomefloxacin 22.35 jug/L (EC50)； 1 . 6 1 jag/L 
(EC,o); 1.99 jag/L (NOEC) 
Norfloxacin 22 jug/L (EC50)； 5.21 jAg/L 
(EC,o); 1.038 |ug/L (NOEC) 
Ofloxacin 13.59 )ag/L (EC50)； 940 ng/L 
(ECio); 1130 ng /L ( N O E C ) 
Oxolinic acid 22.91 jag/L (EC50)； 3 4 2 0 
ng/L (ECio); 731 ng/L 
(NOEC) 
*LOEC: Lowest observed effect concentration 
NOEC: No observed effect concentration 
ECio： 10% Effective concentration 
EC50: 50% Effective concentration 
LC50： 50% lethal concentration 
IC50： 50% Inhibitory concentration 
18 
From the data, the risk of acute toxicity is low, but there is a likelihood o f� t he 
adverse effects of long term exposure on aquatic organisms. For instance, the growth 
rate of Oryias latipes (Japanese medaka) decreased when propranolol concentration 
was as high as 0.5 mg/L, but in a 2-week propranolol (1 pg/L) exposure, medaka 
reproductive study indicated significant changes in plasma steroid levels. In the 4th 
week, the total number of eggs produced and the number of viable eggs that hatched 
decreased at propranolol concentrations as low as 0.5 |ig/L (Huggett et al., 2002). 
1.4 Removal in the Environment 
Most of the studies conducted until now describe the occurrence of compounds in 
environmental compartments (Batt et al., 2006; Rabiet et al,, 2006; Benotti et al., 
2007; Kiimmerer et al., 2009; Santos et al., 2009). Medical substances have been 
measured in sewage effluent, surface water, groundwater and drinking water (Heberer, 
2002), but there is still a lack of understanding and knowledge about drugs in the 
aquatic environment. The compounds cannot be categorized into groups (e.g. group of 
antibiotics such as B-lactams, cephalosporins, penicillins or quinolones; or group of 
anti-metabolites within the group of cytotoxics) with respect to chemical behavior, 
because even smaller changes in the chemical structure may have a significant impact 
on solubility, polarity and other properties which govern their environmental fate to 
some extent. In this case, compounds cannot be handled as a group with respect to 
environmental issues. A closely related chemical structure may be associated with an 
identical or at least similar mode of action (e.g. B-lactam antibiotics). Therefore, we 
can only apply knowledge of one compound to another compound with very similar 
chemical structure. 
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The removal of pharmaceuticals in the environment is the results of clifTcrcnt 
processes, including biodegradation, adsorption, photodegradation, hydrolysis and 
thermolysis. In activated sludge treatment, biodegradation and adsorption are major 
routes for pharmaceuticals removal. Hydrolysis and thermolysis play less role on their 
elimination. 
1.4.1 Adsorption 
Sorption capacity depends on physico-chemical properties and composition of 
organic compound, and pH value of the environment (Gu et al., 2007; Maoz et al,, 
2010). The determination of B-blocker distribution in surface water-sediment systems 
by Ramil et al. (2010) demonstrated a low to high persistence of these B-blockers with 
90o/o elimination ranging from 0.4-10 d (pindolol and atenolol) to >100 d (sotalol, 
propranolol and celiprolol). Furthermore, these pharmaceuticals had higher sorption 
affinities to river sediment which contained 4.36% TOC and 47% clay/silt than to 
sediment which had 0.74% TOC and 10% clay/silt. Differences in the content of 
natural organic matter (NOM) and clay/silt are likely to cause different sorption 
properties (Ramil et al., 2010). 
Sorption coefficients of eight selected pharmaceuticals (acetaminophen, atenolol, 
carbamazepine, ibuprofen, ifenprodil, indomethacin, mefenamic acid and propranolol) 
were higher in sediment/soil with higher organic contents (Yamamoto et al., 2009). 
Their organic carbon-based sorption coefficient (log K � � ) showed a poor linear 
correlation with the octanol-water distribution coefficient (log Kow) at neutral pH. 
These findings suggested that, in addition to hydrophobic interaction, other sorption 
mechanisms such as electrochemical affinity may play an important part in sorption to 
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scdiincnt/soil at neutral pH. Adsorption of tetracycline was strongly pM-dependent 
with maximum adsorption at around pH 4.3, and evidently tetracycline competed with 
H— and electrolyte cations (Na+) (Gu et al., 2007). A decrease of sulfathiazole sorption 
with increasing pH was observed in all sorbents (compost, manure and humic acid) 
(Kahle et a/., 2007a). 
For manure and humic acid, a 5-time increase in ionic strength caused a maximum 
2.5 fold increase in sorption. The increase of contact time would enhance sorption 
which was confirmed by higher K^ values in 14 d than 1 d (Kahle et al., 2007a). 
Sorption of these antibiotics to inorganic sorbents was much lower than to organic 
sorbents, independent of contact time and pH. This indicated that inorganic sorbents 
played a minor role in sorption to eliminate pharmaceuticals in many topsoils and 
sediments (Kahle et al., 2007b). 
In the sewage treatment process, the sorption potential of triclosan did not seem to 
be affected by sludge retention time. Triclosan was significantly removed from the 
dissolved phase at the end of the experiment (lOh) by activated sludge (Stasinakis et 
a/., 2010). Its maximum sorption was observed at 30 min and gradually declined until 
equilibrium after 4 h. Sorption coefficient (Kd) to sludge ranged from 5700 to 8600 
L/kg, depending on sludge age. Gobel et al (2005) determined Kd values of two 
macrolides and sulfonamides between 114 and 460 L/kg in activated sludge, but the 
Kd of macrolides obtained were less variable than sulfonamides which had up to 70% 
variations in the field experiments and two samples. Different sludge characteristics 
and a possible non-equilibrium state in the samples can affect the sorption of the 
investigated antibiotics. 
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Sorption of pharmaceuticals begins to received attention on its influence on 
pharmaceutical removal, but there is a paucity of knowledge about the desorption 
potential from soil, sediment or sludge, and then pharmaceuticals released back into 
the environment. 
1.4.2 Pliotodegradation and hydrolysis 
Photodegradation can occur in sunlit natural surface water by direct and indirect 
photolysis (Lam et al,, 2004; Trovo et al., 2009). Organic compounds adsorbing direct 
sunlight radiation (290-800 nm) may become unstable and subsequently decompose. 
In the indirect photochemical reactions, pharmaceuticals react with transient reactive 
intermediates such as singlet oxygen, hydroxyl radicals, aqueous electrons and other 
reactive species generated by natural water constituents. 
If the compounds are light sensitive, they will be mostly removed by 
photo-decomposition. Information of sensitivity of pharmaceuticals against light can 
be found in the medical and pharmaceuticals literature, but the influence of the 
constituents of natural water like nitrate, dissolved organic matter (DOM) and 
bicarbonate on the elimination rates of the pharmaceuticals are still not well known. 
Photodegradation depends on the intensity of solar irradiation, eutrophic conditions, 
depth of water course, composition of organic matter, latitude and season (Heberer, 
2002; Pent et al., 2006; Mompelat et al., 2009). 
The presence ofhumic matter decreased the photodegradation rates of levofloxacin 
and sulfamethoxazole (Lam et al., 2004). However, the same constituent o fhumic 
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matter had an opposite effect on the elimination rates of atorvastatin and 
carbamazepine. Jiao et al. (2008) studied photolysis behaviors of tetracycline and its 
degradation products. Its photodegradation was highly pH-dependent and strongly 
enhanced at high pH. The results showed that tetracycline photolysis followed a 
first-order kinetics and depended on the initial tetracycline concentration. The 
increasing tetracycline concentration from 10 to 40 mg/L would decrease the 
photolysis rate constant from 0.0045/min to 0.0014/min. 
However, Piram et al (2008) compared photodegradation of B-blockers at two 
concentration levels (10 |Lig/L and 10 mg/L) and found that the concentration did not 
influence their degradation rate. Another drug histamine Hs-receptor antagonists, 
ranitidine and cimetidine had different photodegradation behavior (Latch et al., 2003). 
Ranitidine was observed to degrade in direct photolysis experiments with a half-life of 
35 min under noon summertime sunlight at 45°latitude, while cimetidine was shown 
to be resistant to direct photolysis. In most natural waters, cimetidine mediated by 'O2 
and -OH is the likely photodegradation pathway. Diclofenac was observed with a 
first-order kinetics and a half-life of less than 1 h (October and 4 7 � N latitude) when 
exposed to sunlight (Buser et al,, 1998). These results indicate that photodegradation 
can account for the rapid removal of diclofenac. 
Hydrolysis is another major abiotic removal pathway, usually accompany with 
photodegradation, but there are few investigations. Instability in water could be 
observed for some antibiotics by Halling-Serensen (2000). 
1.4.3 Biodegradation 
2 3 
Microbial degradation of several pharmaceuticals is documented in the literature 
(Halling-Serensen et a!., 1998; Mompelat et al., 2009). It is supposed to be 
insignificant in natural waters like surface water and groundwater due to the low 
density and diversity of bacteria involved (Buerge et al； 2006; Zuccato et al., 2010). 
Some pharmaceuticals present in the soils and sediments are persistent in the 
laboratory test or field study (Hektoena et al., 1995, Loffler et al., 2005; Kunkel et al., 
2008; Ramil et al., 2010). In the STP process, biodegradation plays a major role in the 
elimination of pharmaceuticals. Closed bottle test (OECD 301 D) and Zahn-Wellens 
test (OECD 302 B) are widely used in the assessment of biodegradability under 
ambient and optimized conditions, respectively. 
Alexy et al (2004) tested the biodegradability of 18 antibiotics using the closed 
bottle test and found all antibiotics degraded for less than 60% during the test period 
of 28 days. All of them were classified as not readily biodegradable. The primary 
aerobic and anaerobic biodegradability of olaquindox, metronidazole, tylosin and 
oxytetracycline were studied in a simple shake flask system simulating the conditions 
in surface waters (Ingerslev et al., 2001). The concentrations of antibiotics, the time, 
and location of sampling of surface water did not affect the biodegradation behavior 
of the four antibiotics. But biodegradation was significantly faster in tests conducted 
in the presence of oxygen. 
The degradation products of some pharmaceuticals were investigated, mostly using 
Zahn-Wellens test (Steger-Hartmann et al., 2002; Dodd et al., 2004; Quintana et al., 
2005; DellaGreca et al., 2006; Trautwein et al., 2008; Radjenovic et al., 2008; Li et 
2 4 
‘//., 2008; L-ingin ct 2009; Jcong et "/., 2010), but few studies of the degradation 
pathway and dead end products were found. 
1.5 Analytical Method of Pharmaceuticals in Environmental Samples 
Direct analysis of pharmaceuticals in the environment may not be possible because 
environmental sample matrices. Especially sewage, they are complex and often 
contain elements that can mask or interfere with the compounds of interest in a variety 
of ways. Moreover, the concentrations are generally low to make it necessary to 
purify analytes from environmental samples prior to analysis. But solid-phase 
extraction (SPE) and LC-MS is an effective method to extract the pharmaceuticals 
and prevent interference. 
1.5.1 Solid-phase extraction 
SPE has gradually replaced classical liquid-liquid extraction (LLE) and becomes 
the most common extraction technique in environmental samples (Aga et al., 2008). 
SPE offers the following advantages over LLE (Pavlovic et al., 2007): 
1. higher recoveries; 
2. improved selectivity, specificity and reproducibility; 
3. elimination of emulsions; 
4. less organic solvent usage; 
5. shorter sample preparation time; and, 
6. easier operation and the possibility of automation. 
In SPE, the analytes must have greater affinity for the solid phase than for the 
sample matrix, and then they are separated between a solid phase and a liquid phase 
2 5 
(Pavlovic ct u!., 2007). SPE products are excellent for extraction, concentration and 
clean-up. Figure 1.2 shows the common procedure for SPE. 
The sorbent must be conditioned by proper solvent before loading the samples. 
Table 1.3 gives reference to SPE procedure for the extraction of pharmaceuticals from 
water samples in sewage treatment plants or rivers in the literature. Choice of sorbent 
is the key in SPE because it can control parameters such as selectivity, affinity and 
capacity. This choice depends strongly on the target analytes and the interactions of 
the chosen sorbent through the functional groups of the analytes. 
~ ~ “ ‘ Conditioning the SPE sorbent 
^ P with proper solvent 
i L 
Filtering the samples • Sample loading procedures 
1 r 
Washing the sorbent (removal 
of the interference) 
y r 
Air-drying the sorbent 
l r 
Eluting the analytes from the sorbent 
] r 
Evaporating the elution solvent in 
nitrogen stream 
J r 
Dissolution the dry residues with 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1 lowcvcr, it also depends on the interactions with both the sorbent and the analytcs 
and kind of sample matrix (Leon-Gonzalez et ciL, 2000). Pharmaceuticals with 
adequate hydrophobicity (log Kow in the range 1.5-4.0) can be easily preconcentrated 
using any reversed-phase material (e.g. C8, CI8). Classical SPE sorbents are 
chemically-bonded silica with the C8 or C18 organic group. In most researches, Oasis 
HLB (Hydrophilic-Lipophilic Balance) cartridge is widely chosen for its high 
retention and capacity for a wide spectrum of analytes, especially when the SPE 
column runs dry. The Oasis HLB sorbent is a macroporous copolymer made from a 
balanced ratio of two monomers, the lipophilic divinylbenzene and the hydrophilic 
N-vinylrrolidone optimal for any sample cleanup (Figure 1.3). Compared with 
traditional sorbents silica-based CI8, HLB sorbents can maintain proper wetting for 





Figure 1.3 Chemical structure of Oasis HLB copolymer (Waters, 2009). 
1.5.2 Liquid chromatography mass spectrometry 
In the final determination, liquid chromatography is used to separate the chemical 
compounds in the samples. The mobile phase that carries a mixture in 
chromatography is caused to move in contact with a selectively adsorbent stationary 
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phase. Different components of the sample are carried forward at dilTcrenl rates by the 
moving liquid phase, due to their differing interactions with the stationary and mobile 
phases. The stationary phase is a finely divided solid held inside the column. The 
mobile phase is a solvent which is pumped under high pressure through a column. 
It is similar in selecting the sorbent stationary phase and SPE cartridge. The 
stationary phase is generally made up of hydrophobic alkyl chains 
(-CH2-CH2-CH2-CH3) that interact with the analyte. There are three common chain 
lengths, C4, C8, and CI8. With longer carbon chain, CI8 columns will definitely be 
more "hydrophobic than the C4 and C8 columns. C8 columns are suited for the 
separation of compounds that are too strongly retained on CI8 phases or require 
greater retention than C4. For pharmaceutical analysis, both C8 and CI8 are used for 
separation, especially CI8. 
The most important chromatographic characteristics are column efficiency, 
hydrophobicity, ion-exchange capacity, steric selectivity and the amount of metal 
impurities (Ahuja et al., 2007). Column efficiency is the degree to which species flow 
through the column as “bands” without being spread. Less band broading implies a 
less likely overlap of peaks in the chromatogram. Good steric selectivity of column is 
available to control selectivity and optimize separations of isomers and related 
mixture (Visky et al, 2007). Figure 1.4 shows the chromatography of pharmaceuticals 
separated by CI 8 column. It shows C18 suitable for the separation of pharmaceuticals. 
The CI8 column differs in bonding density, pore size, length and internal diameter. It 






0.50; 2 ？ 
0.25: 1 I 4 6 7 
n nnJ iJLJL'iJ A _ — . j \ 
Figure 1.4 Separation of pharmaceuticals by XBridge™ CI 8 column (Waters, 2.1 mm 
i.d., 50 mm length, 5 |im). Analytes: (1) lomefloxacin, (2) nifedipine, (3) 
erythromycin, (4) azithromycin, (5) roxithromycin, (6) pravastatin, (7) simvastatin. 
The liquid sample separated by chromatograph can be dispersed into ions by 
electrospray ionization (ESI). The electrospray process is capable of transferring 
liquid-phase noncovalent complexes into the gas phase without disrupting the 
noncovalent interaction. It overcomes the propensity of molecules to fragment when 
ionized in comparison with chemical ionization (CI) and electron ionization (EI), and 
is well recognized as a soft ionization method (Veenstra et al., 1999, Harry et al, 
2009). 
Fourier transform ion cyclotron resonance mass spectrometry (FTICR MS) is able 
to provide higher confidence of identification, increase dynamic range and sensitivity 
than any other mass spectrometer (Page et al., 2004). A major advantage of FTICR 
detection is time-dependent measurements based on excitation of all the ions 
simultaneously. The whole mass spectrum is acquired at the same time and it is not 
the case of detection devices based on mass scanning (Dehon et al., 2008). The high 
accuracy of m/z values, being <1 ppm between observed and theoretical values, 
allows the prediction of molecular formulas of unknown compounds for the 
determination of chemical composition (Suzuki et al., 2008). 
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1.6 Objectives and Outline of Thesis 
According to the literature review of pharmaceuticals occurrence in the 
environment, this emerging pollution concerns ecosystem and human health. The 
situation of contamination in China is not investigated extensively. The consumption 
of pharmaceuticals is very large. Only few drugs were detected in STPs and receiving 
rivers (Peng et al, 2006; Xu et al, 2007; Li et al., 2008; Xiao et al., 2008; Zhang et 
al., 2008; Zhao et al., 2009). Information on the inhibitory effect of pharmaceuticals 
on the sludge in STPs is scarce, not to mention the degradation process and potential 
derivates of pharmaceuticals. From these reasons, we set two objectives in this study; 
1) to examine the occurrence of the various PPCPs in sewage, 2) to evaluate 
elimination efficiency in the various treatment processes, and 3) to assess the effect of 
target pharmaceuticals on the sludge and identify unknown derivates. 
The overall aim of this work was to examine the fate and the removal of 
pharmaceuticals (macrolides: azithromycin, erythromycin, roxithromycin; P-blocker: 
atenolol; statin: simvastatin) during sewage treatment in Hong Kong, Guangzhou and 
Shenzhen, as well as the biodegradation pathway of selected pharmaceuticals and 
influence on STPs. According to this aim, the thesis can be divided to three parts. 
The first part presents the concentrations of pharmaceuticals in the influents, final 
effluents and after individual process units of three STPs. The work focused on: 
(1)the investigation of studied pharmaceuticals present in Hong Kong, Shenzhen and 
Guangzhou STPs, 
(2) the investigation of the removal efficiency of primary and secondary treatment 
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processes, 
(3) the comparison of the performances of different treatment processes, including 
conventional activated sludge, AB (adsorption-biodegradation), UNITANK, and 
AVO (anoxic/anaerobic/oxic), and 
(4) the study of the temporal variation and removal of pharmaceuticals 
The second part investigates the extent of five pharmaceuticals in inhibiting the 
growth and nitrification activity of bacterial community in sludge under standard 
tests. 
The third part identifies the degradation or transformation products of four 
pharmaceuticals (erythromycin, roxithromycin, azithromycin, and atenolol) was done 
using Zahn-Wellens test. 
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2 OCCURRENCE AND FATE OF SELECTED PHARIMCEUTICALS IN S I PS 
2.1 Introduction 
In recent years, the contamination of pharmaceuticals and their fate in the 
environment has received increasing attention due to their potential adverse bioactive 
effects oil the aquatic environment (Hilton et al., 2003). The chemical properties of 
pharmaceuticals, intentionally produced to resist rapid metabolism in the body to 
ensure adequate medicinal effect, may be responsible for their environmental 
persistence (Richman et al., 2008). Furthermore, continuous discharge of 
pharmaceuticals from communities and hospitals can result in elevated concentrations 
in the aquatic environment even they are not persistent compounds. During and after 
drug treatment, humans and animals excrete a combination of intact and metabolized 
pharmaceuticals. Many bioactive compounds would enter the wastewaters stream and 
receiving water bodies if they are incompletely eliminated when passing through 
sewage treatment plants (STPs) (Temes et al., 2004). The presence of pharmaceuticals 
in the aquatic environment were observed in China (Xu et al., 2007, Gulkowska et al., 
2007, Minh et al., 2009, Zhao et al., 2009), Japan (Nakada et aL, 2006), South Korea 
(Kim et al.., 2007) and the United States (Conley et al., 2008, Bartelt-Hunt et al., 
2009). Although the environmental concentrations of drugs are generally low 
(micrograms to nanograms per liter) (Jone et al., 2005), their properties and their 
continuous use would eventually result in pharmaceuticals concentrations sufficient to 
provoke toxic effects (Daughton et al., 1999). 
Fate of pharmaceuticals in the STPs depends on performance of plant operation 
(such as hydraulic retention time, sludge age and temperature) and characteristic of 
pharmaceuticals (Andersen et al., 2005; Vieno et al., 2007; Gobel et al., 2005; Wick et 
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2009). During vvaslewalcr treatment process, sometimes primary treatment 
provided no significant elimination to the investigated substances due to low sorption 
coefficients between pharmaceuticals and organic matter (Gobel et al.’ 2005; Kim et 
2010). After the whole treatment process, there is a wide range of elimination rate 
among different pharmaceuticals. Fluoroquinolones were eliminated by 80%, while 
carbamazepine was not eliminated or even increased in concentrations (Vieno et al, 
2007). The consumption of antibiotics increases remarkably in China in the recent two 
decades. We know little about the situation of this kind contamination in Hong Kong 
and mainland China. This experiment studied the occurrence and fate of selected 
pharmaceuticals in STPs in Hong Kong and cities in Guangdong; information 
obtained would help to understand the pollution level and treatment process efficiency 
of the pharmaceuticals in this region. 
2.2 Materials and Methods 
2.2.1 Choice of pharmaceuticals for study 
Erythromycin, roxithromycin (> 90%), atenolol (> 98%), simvastatin (>97%) were 
all purchased from Sigma (Steinheim, Germany). Azithromycin was purchased from 
LGC (London, UK). All solvents, acetonitrile (ACN), methanol and dichloromethane 
(DCM) were HPLC-grade and purchased from Merck (Darmstadt, Germany). Solvent 
additive formic acid was LC/MS quality from Sigma (Steinheim, Germany). Nitrogen 
for drying, purity 99.95% was from Hong Kong Oxygen (Hong Kong). 
Stock solutions of individual standards (1 g/L) were prepared in methanol and 
stored at -20°C. A standard mixture in which the compounds were at a concentration 
of 10 mg/L was prepared from the stock solution. Further dilutions of this mixture 
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were prepared in water and used as working standard solutions. 
2.2.1.1 Criteria of selecting pharmaceuticals 
A combination of factors should be taken into account when selecting 
pharmaceuticals for study, such as their predicted environmental concentrations, 
reported environmental concentrations, reported removal in STPs and potential 
degradation pathway. 
1. Pharmaceuticals chosen for research should be ones that had already been 
detected in the aquatic environment. Due to time limitation, we avoided the risk 
of spending a large amount of time to develop analytical method for a particular 
compound but unable to detect it in the environment. 
2. Compounds with very relatively high removal efficiency during sewage 
treatment plants were of interest in this study. These compounds could be 
investigated for their degradability using Zahn-Wellens test and analyzed by 
FTICR MS/MS. 
3. Compounds with a high predicted or measured environmental concentration 
would be selected because they may pose high potential risk to environment. 
4. Pharmaceuticals which have not been investigated in Hong Kong and Guangdong 
were given higher priority. 
According to above-mentioned criteria, five pharmaceuticals were selected for study, 
viz. azithromycin, erythromycin, roxithromycin, atenolol and simvastatin. 
2.2.1.2 Medical usage of selected pharmaceuticals 
Azithromycin, erythromycin and roxithromycin 
These three drugs belong to antibiotic macrolides which have a large macrocyclic 
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lactoiic ring to which one or more deoxy sugars are attached (see Figure 2.1). I hcy 
are used as common broad-spectrum antibiotics to treat infections caused by bacteria. 
The mechanism of their action is the inhibition of bacterial protein biosynthesis. 
Bacteria are sensitive to the presence of macrolide. The growth of algae 
{Pseiidokirchneriella subcapitata) was inhibited in the concentration of 19 |ig/L 
azithromycin (Harada et al., 2008) and 20 |ig/L erythromycin (Isidori et al., 2005). 
Atenolol 
Atenolol, a widely used P-blocker, is used for the treatment of cardiovascular 
diseases and conditions like hypertension. P-blockers act by competitive inhibition of 
P-adrenergic receptors in heart and juxtaglomerular apparatus. They can decrease 
heart rate and the release of renin from the kidney, thus lowering blood pressure. 
3-blockers may be toxic to organisms possessing P-adrenergic receptors. Most of 
current studies focus on the acute toxicity on the vertebrate and invertebrates but not 
many on chronic toxicity. 
Simvastatin 
Simvastatin belongs to the class of pharmaceuticals -statins used to lower lipid 
level. Statins act by inhibiting the 3-hydroxymethylglutaril coenzyme A (HMG-CoA) 
reductase to block the pathway of cholesterol synthesis in liver. The levels of 
cholesterol in blood plasma decrease when the liver decreases cholesterol production. 
It may bring some common adverse effects like raising liver enzymes and muscle 
problems. Debernard et al. (1994) found lovastatin not only inhibited the HMG-CoA 
3 8 
reductase, but also a flee led juvenile hormone synthesis in insects. Fluvaslatin was 
completely suppressed for juvenile biosynthesis in vitro and the lobster mandibular 
organ (Li et al., 2003). However, the information regarding the ecotoxicity and 
degradation of statins is scarce (Crane et al,, 2006). 
2.2.1.3 Physical and chemical properties 
The fate of pharmaceuticals including bioavailability and persistence, depend on 
their physicochemical properties such as chemical structure, water solubility, 
octanol/water partition coefficient, dissociation constant and Henry's law constant. 
The detailed properties of studied pharmaceuticals are shown in Figure 2.1 and Table 
2.1. Atenolol is water soluble with low log Kow value. The three antibiotics are 
slightly water soluble, with relatively high octanol/water partition. Simvastatin has 
lowest water solubility. From log Kow value, it is more lipophilic than the other four 
compounds and likely to be adsorbed by sludge. Atenolol, aizhromycin and 
erythromycin belong to weak acid with pKa values ranging from 8.74 to 9.6. The 
partition of five compounds into the gas phase can be neglected for their very low 
Henry's law constant. The low volatility of pharmaceuticals indicates that they will be 
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Roxithromycin (ROX) Atenolol (ATE) 
Figure 2.1 Chemical structures of selected pharmaceuticals. 
2.2.2 Description of sewage treatment plants (STPs) 
Five STPs were sampled. They were located in Stonecutters Island, Shatin and Tai 
Po in Hong Kong, as well as Shenzhen and Guangzhou in mainland China. A 





































































































































































































































































































































































































































































































































-.2.2.1 SlonccuUcrs Island S I P 
The Stonecutters Island (SCI) STP adopts chemically enhanced primary treatment 
and operates with an average flow of 1.7 million mVday which is almost 5 times 
higher than that of the Shatin STP and 18 times higher than that of the Tai Po STP. 
The STP treats sewage collected by seven preliminary treatment plants in the main 
urban areas of Kowloon and Northeast Hong Kong Island. Municipal wastewater 
predominates. A flow diagram is shown in Figure 2.2. Because no autosampler was 
available in Stonecutters Island, samples of screened sewage (influent) and effluent 
were collected every two hour from 9:00 to 17:00. The five samples were combined to 




Screened Flocculation Sedimentation 
sewage tank • tank Effluent 
• Sampling point 
Figure 2.2 Flow diagram of sewage treatment process at the Stonecutters Island STP. 
2.2.2.2 Shatin and Tai Po STPs 
Both Shatin (ST) and Tai Po (TP) STPs employ conventional activated sludge 
process. Flow diagram of these two plants is shown in Figure 2.3. The Shatin STP 
serves for a population of 600000 in Shatin and Ma On Shan, which contains no 
known industrial effluent. The Tai Po STP provides treatment to sewage collected 
from Tai Po New Town and the Tai Po Industrial Estate with a total population of 
134000. 
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, Preliminary 森 Primary 
wastewater . ‘ ‘ ‘ •，『^ . 
• treatment 暫 s e d i m e n t a t i o n 
• 
C Aeration • sedimentation Effluent 
tank 
Return activated sludege 
• Sampling point 
^ P ； Anaerobic area (28%) Aerobic area (72%) 
Figure 2.3 Flow diagram of sewage treatment process at the Shatin and Tai Po STPs. 
The retention time of sewage in secondary treatment is about 9 hours. The different 
process of these two plants is that the Shatin STP uses aerated grit removal channels. 
Flow proportional 24-h composite sample were obtained by auto-sampler for effluent 
after preliminary treatment, primary settled wastewater entering aeration tank 
(primary treatment) and final effluent. 
2.2.2.3 Shenzhen STP 
The Shenzhen (SZ) STP receives sewage which is predominantly domestic 
wastewater and with some industrial sewage. It employs adsorption-biodegradation 
process for secondary treatment (Figure 2.4). 
In the adsorption stage with short bacteria generation times, 40-60% B O D 5 and SS 
were removed by adsorption, aggregation and bioadsorption in aerobic condition. 
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After secondary sedimentation，the flow passes through the distribution chamber to 
one of the oxidation ditches. The distribution chamber can change the flow direction 
to different ditches to alter the operation sequence. All three ditches are connected by 
lowering the weir. Brush aerators are located at different points along the ditch to 
extend the aeration process. Changing the speed of brush aerators to alter the oxygen 
content in each ditch can bring to anoxic, aerobic and sedimentation operation modes. 
The hydraulic retention time (HRT) of sewage in the ditch is 4.7 h. Flow proportional 
to 24-h composite sample were obtained by auto-sampler for effluent after 
preliminary treatment, effluent after secondary sedimentation (before entering the 
distribution chamber) and final effluent after oxidation ditches. 
Raw ^ Preliminary Aerated grit _ _ Adsorption stage 
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Figure 2.4 Flow diagram of Shenzhen STP. 
2.2.2.4 Guangzhou STP 
The Guangzhou (GZ) STP has three phases with different treatment methods and is 
one of the largest secondary sewage treatment plants in the Guangdong Province. It 
serves a population of 2.96 million in Guangzhou. The flow diagrams of the three 
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phases arc shown in Figure 2.5. 
Phase I Returned activated sludge 
Raw ^ . 
wastewater _ ^ Preliminary Adsorption stage F " 
• treatment ^ • Sedimentation 
Aeration tank 
) Final 
, Aeration ^ ^ sedimentation •私 Effluent 
\ j tank 
Returned activated sludge 
Phase I I 
waLwater • Pre—inary . 
treatment 
T T 't 
Effluent _ 眷 + ——^ 
B 、 7 C 
Phase I I I 
waLwater Anoxic tank Anaerobic tank 
J 
Effluent Sedimentation ^ O x i c tank 
• Sampling point “ 
Figure 2.5 Flow diagrams of Guangzhou STP- Phase I, II and III. 
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Phase 1 adopts adsorption-biodegradation process. The primary treatment in Phase I 
employs the same treatment in Shenzhen STP- adsorption stage, while the secondary 
treatment adopts the same treatment in Shatin STP. The retention time is not available. 
Phase II employs the UNITANK process. The effluent after preliminary treatment 
would enter each compartment in the reactor in sequence. Each compartment is 
equipped with an aeration system and is hydraulically connected by openings in the 
connecting walls. The outer compartments (A and C) have an overflow system for 
effluent discharge, meaning that the outer compartment can be either as aeration or 
sedimentation tank. UNITANK operates according to a cycle of two main phases 
(HRT 3 h) and two short intermediate phases (HRT 0.5 h) in sequence. The retention 
time is also not available. 
Phase III employs modified A^/0 (anoxic/anaerobic/oxic) technology. In this 
process, biological phosphorus along with simultaneous nitrification and 
denitrification can be removed. The retention time is also not available. 
Samples were collected every 2 hours from 9:00 to 17:00 and samples were 
combined to form a composite sample. 
2.2.2.5 Wastewater characteristics of the five STPs 
The differences in wastewater composition would affect adsorption and 
biodegradation of the targeted pharmaceuticals. The detailed information of individual 
STP is shown in Table 2.3. There is no significant difference from plant to plant. 
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Table 2.3 Wastewater characteristics of the five STPs (Stonecutters Island ⑴，Shatin⑵， 
Tai 1)0(3), Shenzhen� and Guangzhou(5)). 
SS BOD5 CODcr TP TN NH3-N NO3-N 
STP pH 
mg/L mg/L mg/L mg/L mg/L mg/L mg/L 
Ta m 175 4T6 4^4 M ^ T\""" 
Stonecutters EF 7.2 35 45 132 2.7 26.5 18.4 1 4 
Island (1) 
RE% na 82 74 68 39 22 8 na 
IN 7.2 297 162 na 4.7 40 25 <1 
Shatin � EF 7.5 <7 <5 44.2 1.7 <10.2 6.3 1.8 
RE% na 98 97 na 64 75 75 na 
IN 7.2 338 184 na 4.6 41 25 <1 
TaiPo(3) EF 7.1 <10 <5 48.9 2.0 <9 4.7 2.1 
RE% na 97 97 na 57 78 81 na 
IN 7.3 260 211 518 4.55 58 46 0.99 
Shenzhen � EF 7.5 15 16 60 2.26 39.4 33.4 1.72 
RE% na 94 92 88.2 49 32 28 na 
Guangzhou(5) IN 7.0 208 141 209 4.04 28 24 0.17 
EF 7.2 9 7 19.9 0.28 17.4 2.2 14 
Phase I 
RE% na 95 95 90 93 38 90 na 
EF 7.2 15 9.14 26.6 0.26 15.6 0.49 na 
Phase II 
RE% na 93 94 87 94 44 98 na 
EF 7.0 11 8 23 0.15 12.8 0.29 na 
Phase III 
RE% na 95 94 89 96 54 99 na 
*IN: influent; EF: effluent; 
RE: removal efficiency= (original compound concentration — remaining 
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conccntralionVoriginal compound concentration, 
iia denotes not available. 
Source: data of Hong Kong STPs collected from website of Drainage Services 
Department (http://www.dsd.gov.hk/EN/Home/index.html) and data of Shenzhen and 
Guangzhou STPs (personal communication). 
2.2.3 Experimental approach 
2.2.3.1 Sampling period, collection and preservation 
Samples were taken from each STP between August 2009 and January 2010. 
Samples studied included influent, effluent after primary treatment and final effluent. 
Auto-samplers were available at Shatin, Tai Po and Shenzhen STPs to collect flow 
proportional to composite sample, which collects sample for 24 hours with a 1-hour 
interval between each collection and each hour collection volume depends on the flow 
rate. Three replicate samples were collected every two hours from 9:00 to 17:00 (total 
15 samples) and combined 5 samples at each hour to form a replication of composite 
samples (total 3 replicates) at Stonecutters Island and Guangzhou STP where 
auto-sampler was not available. 
Wastewater samples were collected in amber glass bottles that had been 
successively washed with tap water, ultrapure water and hexane. Sampling bottles 
were kept in ice and brought back to the laboratory after collection. In order to avoid 
changes in sample composition, samples were extracted within 48 h. All the samples 
were filtered by GF/D (2.7 jim) and GF/F (0.7 [im) Whatman filter papers. Prior to 
filtration, the filters were soaked overnight in a mixture of hexane/DCM (1:1), dried 
in the oven and then ashed at 500�C for 1 h. Filtered samples were kept overnight at 
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4 % � a n d sample extraction using SPB cartridges (Oasis MLB, Waters, German) were 
carried out the next day. 
2.2.3.2 Sample concentration by solid phase extraction (SPE) 
SPE cartridges were preconditioned with 5 mL of methanol and then 5 mL of 
distilled water. Three replicates of 300 mL influent or primary effluent, or 600 mL 
final effluent were loaded to each cartridge with a flow rate of 3 mL/min. The sample 
bottle was rinsed twice with two aliquots of 50 mL of 5% (v/v) methanol in 
double-distilled water, which passed through the cartridge. After passing through the 
air for at least 0.5 h, the target compounds were eluted from the cartridges using 6 mL 
methanol and 6 mL dichloromethane. The extracts were mixed and dried under a 
gentle nitrogen stream, and then redissolved in 0.5 mL of methanol. Each final extract 
was then filtered through a 0.45|im membrane filter into a 2 mL amber glass vial. The 
vials were kept at - 20�C before analysis. 
5 0 
Sample volume: 
300 niL of influent/ 
300 mL of primary effluent/ 
600 mL of effluent 
J 
Filtration: 0.7 jim glass fiber filter 
1 r 
Solid phase extraction: Oasis HLB 
Wash up: 5 mL methanol, 5 mL DI water 
Elution: 2x3 mL methanol & 2x3 mL dichloromethane 
I 
Evaporation to dryness with N2 gas 
J r 
Dissolve in 0.5 mL DI water 
1 r 
Analysis by LC-FTMS 
Figure 2.6 Procedure of sample extraction and analysis method. 
2.2.3.3 Analysis of pharmaceuticals 
Analysis of analytes was performed using an UltiMate 3000 Dionex liquid 
chromatograph (Bruker Daltonics, Billerica, Massachusetts) interfaced with a 
Fourier-Transform Ion Cyclotron Resonance mass spectrometer (FTICR MS; Bruker 
Daltonics) which was equipped with an electronspray ionization source (ESI; Bruker 
Daltonics) operated in both negative and positive modes. It uses different energy of 
fragmentation in tandem mass spectrometer among target compounds. Separated 
analysis of individual pharmaceuticals was not available, due to the high cost and 
limited usage time of FTICR MS. Furthermore, FTICR MS has high-resolution and 
high accuracy to confirm the identity of a compound accompany with LC retention 
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time. 1'riCR MS was used for chemical analysis. 
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Figure 2.7 Sample analyses by a Bruker Daltonics FTICR MS. 
A 20 |iL aliquot of extract was injected onto a reverse phase XBridge^^ CI8 
column (Waters Corp., 2.1 mm i.d. 50 mm length, 5 jim) equipped with a guard 
column. Distilled water acidified with 0.1% (v/v) formic acid and ACN acidified with 
0.1% (v/v) formic acid were used as mobile phases at a flow rate of 0.2 mL/min. The 
gradient program was as follows: 5% ACN held for 3 min, increased linearly to 40% 
by 5 min and then to 80% by 11 min and held for 10 min, and stepped to 95% and 
held for 3 min. A 10-min equilibration step at 5% ACN was used at the beginning of 
each run to bring the total run time per sample to 38 min. 
The detection method of FTICR MS was described as follow. The mobile phase 
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and analytos were broken into small droplets with the help of nitrogen nebulizer gas 
fknv (3 L/miii). Nitrogen drying gas (200°C) at a flow rate of 6 L/min was used to 
desolvate droplets produced by the ESI source. The other parameters were set as 
follows: ionization mode (positive ion electronspray), capillary entrance voltage (4.2 
kV) and spray shield voltage (3.5 kV). 
2.2.3.4 Method validation and data quantification 
The SPE extraction efficiency were determined by spiking standard solution 
containing all studied pharmaceuticals into Milli-Q water, influent and effluent 
sample to a final concentration 1 jag/L. Spiked samples were analyzed by the above 
mentioned method. Recoveries of the target pharmaceuticals in blank, influent, and 
effluent samples are listed in Table 2.4, with method detection limit (MDL). 
Recoveries of selected pharmaceuticals varied from 72±8% to llO+lP/o in the 
samples. The method detection limit was defined as 3 times the procedural blank 
value or the noise level in the baseline of the FTICR MS. MDLs ranged from 5 to 100 
ng/mL in Milli-Q water. FTICR MS has high resolution to accuracy of 10 ppm of 
molecular weight. Calibration curves were constructed with 6 calibration points and 
linearity was confirmed with R^ > 0.99. 
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Table 2.4 ITICR MS parameters, linear R^ of standard curves, method detection 
limit (MDL, ng/Ml, in Milli-Q water) and recoveries* of selected pharmaceuticals 
spiked in Milli-Q water (procedure recovery), influent (influent recovery) and effluent 
(effluent recovery). 
Pharmaceutical AZI ERY ROX ATE SIM 
Confirmation ion 7 4 9 . 5 1 2 7 3 4 . 4 6 8 8 3 7 . 5 3 2 2 6 7 . 1 7 419.279 
Retention time (min) 10.62 11.52 12.17 6.52 16.39 
Linear r 2 0.9983 0.9982 0.9959 0.999 0.9968 
MDL (ng/mL) 100 10 25 5 10 
Procedure recovery (%) 110±11 105±8 104±4 79±10 75±9 
Influent recovery (%) 105±6 75±10 85±6 83±8 72±8 
Effluent recovery (%) 108±9 97士9 95士4 92士 12 92±3 
* Recovery: amount of detected compound/ amont of spiked compound. 
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2.3 Results and Discussion 
The occurrence of target pharmaceuticals was investigated to assess their fete and 
influence on STPs located in Hong Kong and the Guangdong Province. The errors 
were around 5-10% for the pharmaceutical concentrations, based on repeated analysis 
of the samples collected. 
2.3.1 Occurrence of azithromycin 
The fluctuations in the concentrations of azithromycin at Stonecutters Island STP 
are shown in Figure 2.8a. The influent concentrations of Stonecutters Island STP 
ranged from 1016 to 1371 ng/L, with median and mean concentration of 1303 and 
1255 ng/L. The slight variation in influent azithromycin concentrations may be caused 
by variations in daily flow (1330000 to 1541000 mVday). The azithromycin 
concentrations of effluent were in the range of 544 to 1084 ng/L. The mean of 
azithromycin concentrations in effluent within the six month period was 849 ng/L, 
and the median value was 875 ng/L. The removal rates of azithromycin at 
Stonecutters Island STP fluctuated from 16 to 56%, with an average value of 30%. 
The concentrations of azithromycin at Shatin STP are shown in Figure 2.8b. The 
influent concentrations of azithromycin ranged from 456 to 1380 ng/L, with median 
and mean value 1045 and 992 ng/L, which were lower than those at Stonecutters 
Island STP. In settled sewage after primary treatment azithromycin concentrations 
were in the range 630 to 1248 ng/L, the median value 887 ng/L. The mean of primary 
treatment concentrations indicated only a medium removal of 12% had occurred 
during settlement. 
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Figure 2.8 Concentrations and removal rate of azithromycin at STPs in Stonecutters 
Island (a), Shatin (b), Tai Po (c), Shenzhen (d) and Guangzhou (e) from August 2009 
to January 2010. IN: influent (n=3), PR: primary treatment (n=3), EF: effluent (n=3), 
EFI: Phase I effluent (n=3); EFII: Phase II effluent (n=3); EFIII: Phase III effluent 
(n=3), Mean: average of concentration in six months (n=18); Primary treatment 
removal rate% = 100% X (azithromycin conc. in influent - azithromycin conc. in 
primary effluent)/ azithromycin conc. in influent; Secodary reatment removal rate% = 
100% X (azithromycin conc. in primary effluent - azithromycin conc. in effluent)/ 
azithromycin conc. in effluent, Total removal rate% = 100% X (azithromycin conc. in 
influent - azithromycin conc. in effluent)/ azithromycin conc. in influent. 
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Concentrations of azithromycin in the eflluent, after biological treatment, were 
significantly lower. The concentrations ranged from 276 to 653 ng/L, with median and 
mean value 354 and 382 ng/L, which were much lower than those at Stonecutters 
Island STP. After this process, the average of 57% azithromycin was significantly 
degraded by the activated sludge process. Overall, removal rate of azithromycin in 
Shatin STP was around 62%, mostly attributed to secondary treatment. 
Azithromycin concentrations at the Tai Po STP are shown in Figure 2.8c. The 
influent concentrations of azithromycin ranged from 673 to 1212 ng/L, with median 
and mean value 950 and 917 ng/L, which were slightly lower than those of Shatin STP. 
After primary treatment, no significant azithromycin removal was observed with a 
median removal value 7%. 
Concentrations of azithromycin in the final effluent ranged from 261 to 439 ng/L, 
with median and mean value 362 and 358 ng/L. Tai Po STP removed 57% 
azithromycin by biological treatment and its verall elimination rate was 61%. 
The influent concentrations of azithromycin at the Shenzhen STP ranged from 872 
to 1235 ng/L, with median and mean value 1065 and 1057 ng/L in Figure 2.8(d). The 
situation was similar to those at the Shatin STP. Azithromycin concentrations in 
preliminary settled sewage were lower than those at Shatin STP. A removal rate 23% 
was obtained indicating the adsorption stage could remove a certain amount of 
azithromycin. 
Concentrations of azithromycin in the effluent from oxidation ditch, ranged from 
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315 to 546 ng/L (median and mean: 410 and 390 ng/L). Removal rates (around 50%) 
of azithromycin in oxidation ditch were substantial, though slightly lower than those 
at Shatin and Tai Po STPs. 
Concentrations of azithromycin at Guangzhou STP are shown in Figure 2.8e. The 
influent concentrations of azithromycin in the three phases varied from 882 to 1374 
ng/L, with median and mean value 1254 and 1211 ng/L. The influent concentration of 
azithromycin was close to the Stonecutters Island STP. Concentrations of 
azithromycin in the final effluent of the three phases were different according to their 
different design and operations. 
Phase I adopted adsorption-degradation process, with effluent containing 233-798 
ng/L (median and mean: 660 and 601 ng/L) and a mean removal rate of around 50%. 
Azithromycin concentrations of effluent after Phase II which adopted UNITANK 
treatment varied considerably from 470 to 1106 ng/L, with median and mean value of 
783 and 790 ng/L. Hence the removal rates were ranging from 20% to 47% and the 
mean removal rate was 35% which was lower than that of Phase 1. The effluent 
concentration of azithromycin at Phase III ranged from 253 to 702 ng/L, with median 
and mean of 559 and 512 ng/L. Phase III had the highest azithromycin removal rate 
(58%) among the three phases. 
2.3.2 Fate of azithromycin 
Azithromycin was detected in all STP samples analyzed, with concentrations with 
ranging from 233 to 1489 ng/L. Influents contained higher concentration of 
azithromycin than effluents. Generally, Stonecutters Island and Guangzhou STP had 
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highest influent concentration (approximately 1250 ng/L) in all studied S IPs. 
Maximum concentrations of azithromycin were previously reported for S I Ps 
influents: 380 ng/L in Switzerland (Gobel et al； 2004), 260 ng/L in France (Miege et 
2009), 260 ng/L in Japan (Yasojima et al., 2006)，53 ng/L (Loganathan et al., 2009) 
and 1110 ng/L in USA (Bhandari et al., 2008). All our detected azithromycin 
concentrations in the influents were higher than reported. High concentrations in 
Hong Kong STPs may be caused by high population density in the city and a lower 
dilution from used water. The higher levels of azithromycin in Guangzhou and 
Shenzhen possibly reflect larger consumption, considering the bigger population and 
reported abuse of antibiotic in mainland China (Zhang et al., 2005). 
Among the five STPs studied, Shatin and Tai Po STPs released the lowest 
azithromycin (around 360 ng/L), but were still higher than reported effluents 170 ng/L 
in Switzerland (Gobel et al., 2004), 138 ng/L in France (Miege et al., 2009), 82 ng/L 
(Loganathan et al., 2009) and 1230 ng/L (Bhandari et al., 2008) in USA. Since few of 
the previous studied detected azithromycin, we still need more comprehensive data 
for better interpretation of the occurrence and concentrations of azithromycin. 
Elimination of azithromycin at Stonecutters Island STP (range: 16-56%; mean: 
32%) was higher than those at other three STPs (except Guanghzhou) in primary 
treatment, but was similar to STP in Switzerland that had 10 to 33% elimination rate 
(Gobel et al., 2007). At Stonecutters Island STP, organic contaminants are adsorbed 
by polymer and ferric chloride to form floes which then settle. Therefore the removal 
of azithromycin by polymers can be correlated with octanol-water partition log Kow 
value. The significant sorption potential can be assessed by the following general 
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guide: log Kow > 4.0 yields high sorption potential, log Kow >2.5 and <4.0 yields 
medium sorption potential, and log Kow <2.5 yields low sorption potential (Rogers el 
(//., 1996). The log Kow 4.02 of azithromycin indicated that the removal may be 
partially attributed to azithromycin partition to polymers. Furthemore, it is known that 
azithromychi may chelate divalent and trivalent metallic ions (Cu^^, Ni^^, Zn^^, A p ^ 
Fe3+, etc. ) and form metal complexes and chelates (Djokic et al., 1996). Ferric 
chloride is known as a flocculant to make tiny particles clump together and precipitate 
in STP. Azithromycin removal may be also achieved by chelating with Fe^^. An 
average removal of 30% of azithromycin suggested most of azithromycin had not 
been eliminated by chemically enhanced primary treatment, although sorption and 
chelation may occur in the treatment process. But the capacity of sorption and 
chelation is limited. They are saturated when sorption and chelation sites are occupied. 
Furthermore, the competitions exist between azithromycin and other organic 
compounds. 
The removal rate was low in the primary treatment process in Shatin (median: 15%) 
and Tai Po STPs (median: 7%) because the primary treatment is done mainly 
physically and mechanically by means of filtration and sedimentation. Slight 
biodegradation may be responsible for removal in Shatin STP, since there is oxygen 
available during grit removal because it employs aerated grit channel, although the 
retention time is rather short. This may be related to the difference removal rate of 
azithromycin at Shatin and Tai Po STP during primary treatment. 
Regarding the Shatin STP settled sewage sampled in November 2009, 
azithromycin may be desorbed from suspended solid, which results in a negative 
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removal rate after primary treatment. Gobel et cd., (2005) also found negative 
eliminations for sulfomethoxazole in primary treatment. They attributed this to the 
simultaneous presence of deconjugable substances of these compounds in the raw 
influent. 
A removal rate 23% at Shenzhen STP indicats that not much azithromycin can be 
removed in the adsorption stage. With adsorption, aggregation and bioadsorption 
under aerobic condition in primary treatment, Shenzhen STP was more effective on 
azithromycin elimination than Shatin and Tai Po STPs which had only aeration in 
primary treatment. 
On the whole, chemically enhanced primary treatment at Stonecutters Island STP 
achieved a higher azithromycin removal rate than Shatin, Tai Po and Shenzhen STPs 
after primary treatments. 
Removal rates (around 50%) of azithromycin during oxidation ditch were slightly 
lower than conventional activated sludge at Shatin and Tai Po STPs which were 
different from previous studies. Drewes et al (2005) studied ibuprofen and naproxen 
removal at STPs using different treatment facilities. Nitrifying and denitrifying plants 
showed significantly lower effluent concentration as compared to trickling filter or 
activated sludge facilities. As oxidation ditch can perform nitrification and 
denitrification, it may cause diverse bacterial compositions within a nitrifying and 
denitrifying system. The different bacterial population would act synergistically and 
result in a greater degree of degradation (Jones et al., 2005). 
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Overall removal rates at the Shalin, Tai Po and Shenzhen STPs were mostly 
achieved by secondary treatment. Although Tai Po STP receives sewage from the Tai 
Po Industrial Estate, its mean removal rate (61%) was similar to that of the Shatin 
STP (62%). Both STPs employ conventional activated sludge with similar influent 
properties. This suggests that the industrial wastewater from the industrial estate did 
not have obvious effect on azithromycin removal. 
Since there was no available auto-sampler for 24 h sampling, it was difficult to 
know the total amount of azithromycin that entered the Guangzhou STP. The exact 
removal of azithromycin was not possible to determine. However, it was possible to 
see that azithromycin was partially removed, since concentrations in the effluent were 
much lower. The lower removal rate (35%) at Phase II may be attributed the short 
hydraulic retention time of only 0.5 hour. 
Removal rates of the five STPs ranged between 30% and 62%. A very inconsistent 
picture is obtained with removal rates of azithromycin varied from -26% to 55% in 
the literature (Gobel et al., 2007; Bhandari et al., 2008; Miege et al., 2009). In one 
conventional activated sludge STP with different sampling dates, the solid retention 
time differed and caused the fluctuation of removal efficiency. The solid retention 
time of 21 and 25 days resulted in elimination rates of azithromycin 22 and 55%, 
respectively (Gobel et al., 2007). 
2.3.3 Occurrence of erythromycin 
The concentrations of erythromycin measured after chemically enhanced primary 
treatment at Stonecutters Island STP are shown in Figure 2.9a. The influent and 
6 3 
emueiU conconlrations ol、erythromycin ranged from 354 to 543 ng/L and 310 to 465 
iig/L. Only 12% o f the influent erythromycin was removed. 
Erythromycin concentrations at Shatin STP are shown in Figure 2.9b. The influent 
concentrations ranged from 387 to 610 ng/L, with median and mean value of 437 and 
460 ng/L. Primary treatment only eliminated 4% of the influent erythromycin 
(ranging from 1% to 8%). 
Lower concentrations of erythromycin were generally observed in the effluent 
compared to the influents. The mean of overall elimination of erythromycin was 
approximately 31%. Effluents ranged from 261 to 370 ng/L (median: 285 ng/L). 
Concentrations of erythromycin at Tai Po STP are shown in Figure 2.9c. The 
influent concentrations ranged from 346 to 534 ng/L, with median and mean value of 
480 and 477 ng/L. Removal rates (median of 7%) were minimal, ranging from -1 to 
10% after primary treatment. Effluent concentrations of erythromycin ranged from 
248 to 462 ng/L (median and mean: 355 and 356 ng/L) which were slightly higher 
than that in Shatin STP. The median of overall removal rate was 28%. 
Concentrations of erythromycin at Shenzhen STP are shown in Figure 2.9d. The 
influent concentrations varied from 339 to 624 ng/L, with median and mean value of 
496 and 483 ng/L. A median removal rate (6%) at Shenzhen STP was similar to the 
4% at Shatin and 7% at Tai Po STPs during primary treatment. 
6 4 
(a) _ SC-IN S SC-EP Removal rate % 
600 Q 
Ii 鋼 � t ^ " ^ ^ “ ^ ^ ^ ~ ^ ^ • • 20 , 
1 _ |L J 6 � I 
_ P _ ：丨圏1 “ 
u iiid m:>:>i 圓：；：；：丨 1:>:>3 刚 
Aug Sept Oct Nov Dec Jan Mean 
Sampling date 
(b) _ ST-IN _ ST-PR 
E 3 ST-EF • -A- Primary treatment removal rate % 
Secondary treatment removal rate % Removal rate % 
3 7 0 0 r • •. • • … … • -1 0 
rnf^m 
Aug Sept Oct Nov Dec Jan Mean 
Sampling date 
Figure 2.9 Concentrations and removal rate of erythromycin at STPs in Stonecutters 
Island (a), Shatin (b), Tai Po (c), Shenzhen (d) and Guangzhou (e) from August 2009 
to January 2010. IN: influent (n=3), PR: primary treatment (n=3), EF: effluent (n=3), 
EFI: Phase I effluent (n=3); EFII: Phase II effluent (n=3); EFIII: Phase III effluent 
(n=3), Mean: average concentration in six months (n=18); Primary treatment removal 
rate% 二 100% X (erythromycin conc. in influent - erythromycin conc. in primary 
effluent)/ erythromycin conc. in influent, Secodary reatment removal rate% = 100%X 
(erythromycin conc. in primary effluent - erythromycin conc. in effluent)/ 
erythromycin conc. in effluent, Total removal r a t e � / � = 100% X (erythromycin conc. in 
influent - erythromycin conc. in effluent)/ erythromycin conc. in influent. 6 5 
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nniuent concentrations of erythromycin ranged Iroin 257 to 426 ng/L, with 
median and mean value of 386 and 359 ng/L. About 25% of erythromycin was 
removed by the sewage treatment process. 
Eiythromyciii concentrations at the Guangzhou STP are shown in Figure 2.9e. The 
influent concentrations ranged from 466 to 670 ng/L, with median and mean value of 
596 and 595 ng/L. The influent at Guangzhou STP had higher concentrations of 
erythromycin than the other four STPs. This is probably due to the higher population 
density served by the Guangzhou STP, and a greater consumption of the drugs by the 
community. 
At Phase I, effluent concentrations ranged from 298 to 510 ng/L, with median and 
mean value of 398 and 408 ng/L. Its mean removal rate (32%) of erythromycin was 
relatively higher than those at the other four STPs. Concentrations of effluent at Phase 
II varied from 309 to 553 ng/L, with median and mean value of 428 and 430 ng/L. 
The removal rates ranged from 16% to 37% and the mean removal rate was 28% 
which was lower than Phase 1. The effluent concentration of erythromycin at Phase III 
fluctuated between 264 and 513 ng/L, with median and mean value of 384 and 389 
ng/L. Phase III had the highest erythromycin removal rate (35%) among the three 
phases. 
2.3.4 Fate of erythromycin 
Erythromycin was detected in all STP samples analyzed, with concentrations 
ranging from 261 to 670 ng/L. Influents had higher erythromycin concentration than 
effluents. Overall, the Guangzhou STP had the highest influent concentration (about 
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600 ng/L) among all S TPs. Much higher than the Guangzhou STI), the inlluenls 
concentration of erythromycin at activated sludge process STP reached 1382 ng/L in 
Chongqing region of Three Gorge Reservoir in mainland China (Chang el al., 2010). 
High erythromycin concentrations from STP influent were also shown in other studies. 
In Spain, erythromycin concentrations (mean: 820 ng/L) ranged between 320 and 
2700 ng/L (Radjenovic et al,, 2009). In France, lower influent concentrations (mean: 
108 ng/L) were observed ranging from 71 to 141 ng/L (Miege et al., 2009). 
Erythromycin readily becomes dehydration product erythromycin-HiO by an apparent 
loss of one molecule of water in aqueous solution at pH < 7.0 (Hirsch et al., 1999). In 
our samples, pH values were higher than 7.0. Erythromycin was not dehydrated and 
therefore could be easily determined. In some studies, concentrations of erythromycin 
were reported as its dehydration product. Miege et al. (2009) detected 
erythromycin-H20 (mean: 545 ng/L; range: 455- 1200 ng/L) with concentrations 
higher than its parent compounds in a French STP influent. Erythromycin detection 
depends on dominated form in the environment. In Taiwan, high erythromycin-H20 
concentrations were determined ranging between 226 and 1537 ng/L in four STPs 
(Lin et al” 2009). In the samples of two STPs in Guangzhou, erythromycin-HzO 
concentrations reached 751 and 1978 ng/L (Xu et al., 2007). This indicats the use of 
erythromycin in Guangzhou district was common and popular. 
Measured mean influent and effluent concentrations ranged from 354 to 543 ng/L 
and 310 to 465 ng/L at the Stonecutters Island STP, which were lower than the 
erythromycin-HiO mean concentrations in the influent and effluent of 550 and 510 
ng/L, respectively (Gulkowska et al., 2008). The detected effluent concentrations 
were also slightly lower than those previously reported at Stonecutters Island STP 
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sewage oniiients (mean: 455 ng/L; range: 246-630 ng/L; Minh el al., 2009). Only 
12% of the influent erythromycin was removed. Octanol-water partition log Kow of 
erythromycin is 3.06, which is lower than 4.02 for azithromycin. According to general 
mle, compound with log Kow between 2.5 and 4.0 yields medium sorption potential 
(Rogers et al, 1996), so erythromycin is harder to be removed than azithromycin via 
adsorption. 
The Shatin STP influent concentrations (mean: 460 ng/L) were lower than those 
recorded by Gulkowska et al. (erythromycin-FtO mean: 740 ng/L). At the Tai Po STP, 
measured influent (mean: 477 ng/L; range: 346 to 534 ng/L) showed lower 
concentrations than those in Minh et al. (2009) (mean: 530 ng/L; range: 506-549 
ng/L). Shenzhen STP influent concentrations (mean: 483 ng/L; range: 339 to 624 ng/L) 
were also lower than the influent concentration (590 ng/L) of another Shenzhen STP 
at Nan Shan (Gulkowska et al., 2008). A median removal rate (6%) at the Shenzhen 
STP was similar to 4% at Shatin and 7% at Tai Po STPs after primary treatment. 
These removal rates were close to those at the Swiss STPs (-8 to 4%) (Gobel et al., 
2007). 
Shatin STP had the lowest effluent concentration (median: 285 ng/L) in all STPs 
studied. Measured concentrations were lower than previous findings in effluents 
erythromycin-H20 by Minh et al. (2009) (mean: 516 ng/L; range: 335-752 ng/L) and 
Gulkowska et al (2008) (mean: 600 ng/L). Mean of detected effluent concentrations 
• obtained at Tai Po STP were also lower than by Gulkowska et al (mean: 520 ng/L; 
2008). By comparing removal rates in the biological treatment, conventional activated 
sludge at Shatin STP (30%) was more effective than the oxidation ditch at Shenzhen 
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S TP (18%). 
The mean of overall elimination potential of erythromycin varied between 12-35%. 
This is still very contradictory for the literature data. Previous findings varied from 
-550/0 to 750/0. Positive removal efficiency were detected in Shatin (19%; Gulkowska 
et al., 2008), Spain (35% removal rate by conventional activated sludge and 43% by 
membrane bioreactor) (Radjenovic et al., 2009)，mainland China Chongqing region 
(390/0; Chang et al., 2010) and Wisconsin USA (75%; Karthikeyan et al., 2006). STPs 
with negative elimination included plants in France (-55%; Miege et al., 2009), 
Switzerland (-22%; Gobel et al., 2007), in Tai Po (-10%; Gulkowska et al., 2008), Tai 
Wan (0%; Lin et al., 2009) and Italy (0%; Castiglioni et al., 2006). One explanation 
for the increase in erythromycin concentration during sewage treatment may be the 
negligence of the hydraulic retention time during sampling, such that the influent and 
effluent samples are not directly comparable (Clara et al., 2005b). The lag time 
between sewage entering and exiting the STP influenced upon the pharmaceutical 
concentrations (Loganathan et al., 2009). In some studies, the measured 
concentrations were low and sometimes close to the limits of quantification, and 
consequently the removal efficiency is questionable (Radjenovic et al., 2009). 
2.3.5 Occurrence of roxithromycin 
Concentrations of roxithromycin at the Stonecutters Island STP are shown in Figure 
2.10a. Influent concentrations (mean: 266 ng/L; range: 195- 378 ng/L) were lower 
than those of erythromycin in our five studied STPs. Effluent concentrations ranged 
from 171 to 324 ng/L (mean: 233 ng/L), but only 12% roxithromycin were removed. 
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Figure 2.10 Concentrations and removal rate of roxithromycin at STPs in Stonecutters 
Island (a), Shatin (b), Tai Po (c), Shenzhen (d) and Guangzhou (e) from August 2009 
to January 2010. IN: influent (n=3), PR: primary treatment (n=3), EF: effluent (n=3), 
EFI: Phase I effluent (n=3); EFII: Phase II effluent (n=3); EFIII: Phase III 
effluent(n=3), Mean: average concentration in six months (n=18); Primary treatment 
removal rate% = 100% X (roxithromycin conc. in influent - roxithromycin conc. in 
primary effluent)/ roxithromycin conc. in influent, Secodary reatment removal rate% 
=100% X (roxithromycin conc. in primary effluent - roxithromycin conc. in effluent)/ 
roxithromycin conc. in effluent, Total removal rate% = 1 0 0 o/o X (roxithromycin conc. 
in influent - roxithromycin conc. in effluent)/ roxithromycin conc. in influent. 
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The concentrations of roxithromycin at Shatin STP are shown in Figure 2.10b. The 
influent concentrations ranged from 184 to 378 ng/L (mean: 273 ng/L), which was 
similar to those at Stonecutters Island STP. Primary treatment only removed around 
9% of the influent roxithromycin, but it remarkably varied from -11% to 19%. The 
concentrations of effluent varied from 91 to 227 ng/L, with median and mean value of 
196 and 173 ng/L. The mean of overall elimination of roxithromycin was 
approximately 38%. 
The measured concentrations of roxithromycin at Tai Po STP are shown in Figure 
2.10c. The influent concentrations ranging from 104 to 290 ng/L (mean: 203 ng/L) 
were slightly lower than those at Shatin STP. But at Tai Po STP lower removal rates 
were observed during primary treatment, considerably varying from -19 to 16%. 
Effluent concentrations of roxithromycin in the effluent were ranging from 84 to 207 
ng/L (mean: 124 ng/L). Overall removal rates (around 33%) of roxithromycin were 
slightly lower than those at Shatin STP. 
The influent concentrations of roxithromycin at Shenzhen STP varied considerably 
from 519 to 1203 ng/L (median: 629 ng/L; mean: 749 ng/L) (Figure 2.10d), which 
were much higher than influents in studied Hong Kong STPs. Approximately 17% of 
roxithromycin were removed through adsorption stage. The amount of roxithromycin 
in the effluent ranged from 294 to 480 ng/L (mean: 381 ng/L) and around 47% 
roxithromycin (range: 30-60%) were removed. 
The measured concentrations of roxithromycin at Guangzhou STP are shown in 
Figure 2.10e. The influent concentrations of roxithromycin at the three phases varied 
7 3 
from 453 to 1006 ng/L, with median and mean value 609 and 678 ng/L. The inllucnl 
concentrations were similar to Shenzhen STP, but were higher than influent in Hong 
Kong STPs. 
At Phase I, effluent concentration ranged from 270 to 522 ng/L (mean: 344 ng/L) 
and the mean removal rate was about 49%. The concentrations of effluent at Phase II 
varied from 267 to 587 ng/L, with median and mean value of 357 and 384 ng/L. Its 
mean removal rate was about 43% which was slightly lower than Phase I. The effluent 
concentrations at Phase III ranged from 218 to 474 ng/L (mean: 328 ng/L). Phase III 
had the highest roxithromycin removal rate (51%) among the three phases. 
2.3.6 Fate of roxithromycin 
Roxithromycin were detected in all samples analyzed, with concentrations ranging 
from 84 to 1203 ng/L. Shenzhen and Guangzhou STPs had relatively high 
concentration in the influent (mean: around 620 ng/L), comparing with those in Hong 
Kong STPs (mean: around 230 ng/L). The maximum roxithromycin in Guangzhou 
and Hong Kong was 278 and 156 ng/L, respectively (Xu et al., 2007). Lower influent 
concentrations were obtained in previous study, such as 30 ng/L in Switzerland 
(Gobel et al., 2004), 62 ng/L in France (Miege et al., 2009), and 117 ng/L in Austria 
(Clara et al., 2005b). Primary sedimentation almost did not remove roxithromycin at 
Shatin (9%) and Tai Po (4%) STPs. Better than primary sedimentation, chemically 
enhanced primary treatment had 12% removal rate. These roxithromycin removal 
rates were consistent with the 3% to 9% in Swiss STP for the primary treatment 
(Gobel et al, 2007). Adsorption stage in Shenzhen STP gave the highest removal rate 
of 17% among the three types of primary treatment. 
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Tai Po STP released the least amount of roxithromycin (129 ng/L) in the ellluent 
among the five STPs, which was comparable to the 141 ng/L by Minh et al., (2009). 
But concentrations at Stonecutters Island (233 ng/L) and Shatin (173 ng/L) STP were 
higher than previously obtained in these two plants, which were 100 and 92 ng/L, 
respectively (Minh et al, 2009). Comparing with other macrolides studied, 
azithromycin and erythromycin, the effluent concentrations of roxithromycin were 
low in our study and literature data. In Switzerland, the effluent concentrations ranged 
from below the limit of qualification to 31 ng/L (McArdell et al., 2003). In Canada, 
France and Austria 8, 49 and 57 ng/L roxithromycin were detected, respectively 
(Miao et al., 2004; Clara et al., 2005b; Miege et al., 2009). No roxithromycin were 
detected in Chongqing regiong in China and Kentucky in USA (Chang et al., 2010; 
Loganathan et al., 2009). 
The mean of overall elimination percentages of roxithromycin in Hong Kong 
secondary treatment STPs was approximately 35%, which was slightly lower than the 
45% in Shenzhen and Guangzhou STPs. The high loading of roxithromycin may be 
related to its removal efficiency. Similar removal rates have also been demonstrated in 
previous studies, including 38% at conventional activated sludge STP and 35% at 
fixed-bed reactor STP in Switzerland (Gobel et al., 2007), and 41% at conventional 
activated sludge STP and 74% at membrane bioreactor in Austria (Clara et al., 
2005b). 
2.3.7 Occurrence of atenolol 
The measured concentrations of atenolol at Stonecutters Island STP are shown in 
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iMgure 2.1 la. Atenolol inlluent concentrations ranged between 604 and 1737 ng/L 
(median and mean: 866 and 996 ng/L). Concentrations in the effluent ranged from 
504 to 961 ng/L (median and mean: 559 and 663 ng/L), and about 31% atenolol were 
removed. 
The measured concentrations of atenolol at Shatin STP are shown in Figure 2.11b. 
The influent concentrations ranged from 216 to 805 ng/L (median and mean: 680 and 
583 ng/L), which were lower than those at Stonecutters Island STP. Primary treatment 
only removed around 6% atenolol in the influent, varying remarkable from -2% to 
20%. The concentrations in effluent varied from 74 to 491 ng/L, with median and 
mean value of 616 and 546 ng/L. The mean of overall elimination percentages of 
atenolol was approximately 45%. 
The measured concentrations of atenolol at Tai Po STP are shown in Figure 2.11(c). 
The influent concentrations ranging from 375 to 779 ng/L (median and mean: 528 and 
549 ng/L) were slightly lower than that at Shatin STP, but they had the same mean 
removal rates (6%) after primary treatment. Concentrations in the effluent ranged 
from 183 to 382 ng/L (mean: 264 ng/L). Overall removal rates (around 51%) of 
atenolol were slightly higher than those at Shatin STP. 
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Figure 2.11 Concentrations and removal rate of atenolol at STPs in Stonecutters 
Island (a), Shatin (b), Tai Po (c), Shenzhen (d) and Guangzhou (e) from August 2009 
to January 2010. IN: influent (n=3), PR: primary treatment (n=3), EF: effluent (n=3), 
EFI: Phase I effluent (n=3); EFII: Phase II effluent (n二3); EFIII: Phase III 
effluent(n=3), Mean: average concentration in six months (n=18); Primary treatment 
removal rate% = 100% X (atenolol conc. in influent- atenolol conc. in primary 
effluent)/ atenolol conc. in influent, Secodary reatment removal rate% = 100% X 
(atenolol conc. in primary effluent - atenolol conc. in effluent)/ atenolol conc. in 
effluent, Total removal rate% 二 1 OOo/o X (atenolol conc. in influent - atenolol conc. in 
effluent)/ atenolol conc. in influent. 
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The measured concentrations of atenolol at Shenzhen S IP are shown in Mgurc 
2.1 Id. The influent concentrations maintained between 209 and 291 ng/L (mean: 268 
ng/L) were much lower than influents in the Hong Kong STPs studied. Approximately 
27% of atenolol were removed through adsorption stage. The concentration in 
effluents ranged from 29 to 124 ng/L (mean: 61 ng/L) and around 77% atenolol (range: 
58-88%) were removed. 
The measured concentrations of atenolol at Guangzhou STP are shown in Figure 
2. l ie . The influent concentrations at the three phases varied from 246 to 345 ng/L, 
with median and average values of 272 and 279 ng/L. The influent concentrations 
were similar to those at the Shenzhen STP but were lower than those in Hong Kong 
STPs. 
At Phase I, effluent concentrations ranged from 94 to 132 ng/L (mean: 117 ng/L) 
and the mean removal rate was about 61%. The concentrations of effluent at Phase II 
varied from 97 to 223 ng/L, with median and mean value of 154 and 151 ng/L. Mean 
removal rate was about 53% which was slightly lower than Phase I. The effluent 
concentrations at Phase III ranged from 61 to 112 ng/L (mean: 93 ng/L). Phase III had 
the highest atenolol removal rate (68%) among the three phases. 
2.3.8 Fate of atenolol 
All measured samples contained atenolol in varied concentrations. In general, Hong 
Kong STPs (> 500 ng/L) had higher concentrations than Shenzhen and Guangzhou 
STPs (> 300 ng/L). The consumption of atenolol should be high because its high 
concentration in the Hong Kong STPs. Atenolol is used in treating cardiovascular 
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disease and high blood pressure (hypertension). From the literature data, higher 
atenolol concentrations were observed in the influent. In UK, 8102- 25146 ng/L 
atenolol were detected in the influent (Kasprzyk-Hordern el al., 2009). Mean 
concentration of 795 ng/L (350 - 1710 ng/L) atenolol were detected in Finland (Vieno 
et al., 2007). In Taiwan STPs, atenolol influent ranged from 738 to 2883 ng/L (Lin et 
a!., 2009), which was similar to those in Spain (mean concentration 2000 ng/L) 
(Radjenovic et al., 2009) and Switzerland that reached up to 2545 ng/L (Maurer et al., 
2007). On the other hand, lower concentrations of atenolol (30 ng/L) were detected by 
in France (Miege et al., 2009). 
Lower concentrations (46- 150 ng/L) were found in Shenzhen and Guangzhou 
STPs effluents, which could be attributed to their low influent loading. Atenolol 
concentration in Hong Kong STP followed a descending order of Stonecutters Island 
(559 ng/L) > Shatin (377 ng/L) > Tai Po (256 ng/L). These effluent levels were 
similar to those in Taiwan (210-681 ng/L) (Lin et al., 2009) and 12 STPs in Finland 
(median: 290 ng/L; range: 40-1180 ng/L; Maurer et al., 2007). Atenolol under 
chemically enhanced primary treatment were not substantiallyremoved (31%). Shatin 
and Tai Po STPs had relatively higher removal rates 45% and 51%, respectively, but 
lower than STPs in Shenzhen (77%) and Guangzhou (53-64%). Atenolol with log Kow 
value of 0.96 indicats its low sorption potential (Rogers et al., 1996). The key removal 
pathway could be biodegradation or biotransformation. Removal rates of atenolol 
were quite high and highly variable in previous studies. Oxidation ditch and A O 
process were more effective than conventional activated sludge (Maurer et al., 2007); 
removal was 63% in conventional activated sludge and 77% in oxidation ditch. In 
Spain STPs, removals of atenolol were 0% or 61% in conventional activated sludge, 
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and 65% or 73% in membrane bioreactor (Radjenovic el cil., in 2007 and 2009). Lin cl 
al. (2009) reported removal efficiency as high as 76% in four Tai Wan STPs. Efllucnts 
were reported to contain higher concentration of atenolol than influent in France 
(Miege et al., 2009). 
2.3.9 Occurrence of simvastatin 
The measured concentrations of simvastatin at Stonecutters Island STP are shown 
in Figure 2.12a. Influent concentrations ranged between 132 and 337 ng/L (median 
and mean: 225 and 232 ng/L), while the effluent had 78 - 235 ng/L (median and mean: 
149 and 155 ng/L) with a removal rate of about 36%. 
Influent concentrations of simvastatin 172 to 394 ng/L (median and mean: 208 and 
241 ng/L) at the Shatin STP (Figure 2.12b), which were similar to those at 
Stonecutters Island STP. Primary treatment only removed around 12% simvastatin. 
The concentrations in effluent varied from 95 to 214 ng/L, with median and mean 
value of 116 and 133 ng/L. The mean of overall elimination was approximately 45%. 
At the Tai Po STP, influent concentrations of simvastatin ranged from 167 to 260 
ng/L (median and mean: 203 and 204 ng/L) (Figure 2.12c), which were slightly lower 
than that at Shatin STP. Removal rate (8%) was lower. Efflluent concentrations were 
89 - 153 ng/L (mean: 109 ng/L). Overall removal rates were around 46% which were 
slightly higher than those at Shatin STP. 
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2.12 Concentrations and removal rate of simvastatin at STPs in Stonecutters Island (a), 
Shatin (b), Tai Po (c), Shenzhen (d) and Guangzhou (e) from August 2009 to January 
2010. IN: influent (n=3), PR: primary treatment (n=3), EF: effluent (n=3), EFI: Phase 
I effluent (n二3); EFII: Phase II effluent (n=3); EFIII: Phase III effluent(n=3), Mean: 
average concentration in six months (n=18); Primary treatment removal rate% = 
100% X (simvastatin conc. in influent - simvastatin conc. in primary effluent)/ 
simvastatin conc. in influent, Secodary reatment removal rate% = 100% X 
(simvastatin conc. in primary effluent - simvastatin conc. in effluent)/ simvastatin 
conc. in effluent, Total removal rate% = 100% X (simvastatin conc. in influent -
simvastatin conc. in effluent)/ simvastatin conc. in influent. 
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The intlucnt concentrations of simvastatin at Shenzhen STl) were maintained 
between 420 and 676 ng/L (mean: 529 ng/L) (Figure 2.12d), which were higher than 
its concentration in influents in Hong Kong STPs studied. Approximately 21 % of 
simvastatin were removed through the adsorption stage. The concentrations in the 
effluent ranged from 182 to 365 ng/L (mean: 269 ng/L); around 49% simvastatin 
(range: 41-57%) were removed. 
For simvastatin at Guangzhou STP, the influent concentrations in the three phases 
varied from 429 to 683 ng/L, with median and average value 459 and 508 ng/L 
(Figure 2.12e). The influent simvastatin concentrations were similar to those in 
Shenzhen STP but were higher than those in the Hong Kong STPs. 
At Phase I, effluent ranged from 235 to 370 ng/L (mean: 327 ng/L) and the mean 
removal rate was about 36%. The concentrations of effluent at Phase II varied from 
281 to 359 ng/L (mean: 315 ng/L). Mean removal rate was about 38% which was 
slightly greater than Phase I. The effluent concentrations at Phase III ranged from 249 
to 340 ng/L (mean: 286 ng/L). Phase III had the highest simvastatin removal rate 
(44%) among the three phases. 
2.3.10 Fate of simvastatin 
Simvastatin was detected in all STP samples, with concentrations ranging between 
78 and 683 ng/L. Hong Kong STPs (around 210 and 130 ng/L) had lower simvastatin 
than Shenzhen and Guangzhou STPs (around 515 and 300 ng/L) in influents and 
effluents. Our influent and effluent concentrations were much higher than those in six 
USA STPs, which were 2.5 and 0.5 ng/L, respectively (Vanderford et al., 2006). 
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Simvastatin were found at high concentrations due to its high usage in the coin in unity. 
In UK，simvastatin concentrations varied in two STPs in different cities 
(Kasprzyk-Hordern et aL, 2009). 
Guangzhou STP released high concentration of simvastatin into the environment, 
(300 ng/L), followed by Shenzhen STP (269 ng/L). Hong Kong STPs had relatively 
lower concentrations: Tai Po (109 ng/L) < Shatin (133 ng/L) < Stonecutters Island 
(149 ng/L). Stonecutters Island STP had high effluent concentrations, with 33% 
removal efficiency. Log Kow of simvastatin is 4.68 which is greater than 4.0 that yield 
high sorption potential (Rogers et al., 1996). Adsorption by polymers may play an 
important part in simvastatin removal. Removal rate were about 45% at Shatin, Tai Po 
and Shenzhen STPs. Guangzhou STP adopting secondary treatment had lower but 
variable removal rate probably because the auto-sampler is not available when 
sampling. Trickling filter beds in UK resulted in higher removal efficiency (95%) 
with effluent concentrations ranging from 3- 20 ng/L (Kasprzyk-Hordern et al., 2009). 
2.3.11 Fate of pharmaceuticals during different treatment process 
In this study, samples were collected from two main categories of STPs: primary 
chemical STP and secondary biological STPs. The total elimination rates of these five 
pharmaceuticals in biological STPs were all greater than those in primary STP, 
whereas elimination efficiencies in chemically enhanced primary STP were higher 
than those in conventional primary sedimentation. The addition of polymer and ferric 
chloride facilitates the transfer of pharmaceuticals from wastewater to ettleable solids 
for sedimentation. 
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Secondary biological treatment methods include conventional activated sludge, 
adsorption-biodegradation, UNITANK process and modified A^/O (anoxic/ anaerobic/ 
oxic) in this study. The total removal efficiencies of different treatment processes are 
shown ill Table 2.5. The removal efficiency of different pharmaceuticals varied. In 
general, adsorption-biodegradation (T-oxidation ditch) and A /O (anoxic tank, 
anaerobic tank, oxic tank) have higher removal performance. Both carry out anoxic 
and aerobic operation mode which can enrich microbial diversity to benefit removal 
of organics, including pharmaceuticals. The advantage of all in one treatment -
UNITANK process is saving space but it may reduce treatment efficiency. The 
conventional activated sludge treatment process had higher removal efficiency for 
azithromycin and simvastatin. 
The different removal efficiencies in biological treatment processes are also related 
to the operation of STP, such as sewage hydraulic retention time and sludge age. The 
relationship between hydraulic retention time and removal has been shown 
(Metcalfe et al., 2003; Temes et al,, 2004). An increase in retention time would 
increase removal, which is evidenced by our study. The hydraulic retention time in 
oxidation ditch was around 4.7 h at Shenzhen STP, and 9 h at Shatin and Tai Po STPs. 
Longer contact time with biomass will improve elimination efficiency. The increase 
of sludge age would enhance the elimination due to greater microbial populations that 
excrete enzyme for breaking down pharmaceuticals (Jones et al., 2007). Sludge age 
longer than 10 d is needed for biodegradation of some pharmaceuticals (Clara et al., 
2005a). In this study, we only know the sludge age of Shenzhen STP (15.5 d); more 
information is needed to confirm the effect of sludge age on these pharmaceuticals. 
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The pl l (around 7.1-7.2) and water temperature of the five S I Ps were similar. 
There was no clear dependency between the characteristics of sewage and removal 
efficiency. 
2.3.12 Contribution of industrial (manufacturing) plants to STPs 
There is no significant difference in influent concentrations of five pharmaceuticals 
between the STP in Tai Po and Shatin. This indicates that industrial plants were not 
making a significant contribution to the pharmaceutical concentration in the influent. 
This is consistent to previous findings (Kummerer et al., 2009), which stated that the 
releases from production plants have been considered as being of minor importance. 
However, in China a STP treating oxytetracycline (OCT) production wastewater had 
concentrations up to 19 mg/L OCT in the treated outflow (Li et al., 2008a). China is a 
top producer and consumer of many antibiotic classes; production wastewater cannot 
be neglected because it contains high concentrations of antibiotics (Qiting et al., 1988; 
Li et al., 2008b). In developing countries, the regulations for good manufacturing 
practice (GMP) are not strictly enforced and production efficiency is not as high as in 
developed countries (Kummerer et al., 2008). The situations of pharmaceutical 
production facilities in Shenzhen and Guangzhou are not known. Further 
investigations are needed to understand the major sources of pharmaceuticals in 
Shenzhen and Guangzhou STPs. 
2.3.13 Seasonal variation 
There were no significant differences in the concentrations in influent and effluent 
collected between August to October (summer) and November to January (winter) 
(Figures 2.8-2.12). Seasonal differences in the raw wastewater are the result of the 
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proscription of phamiaceulicals which was higher in winter but lower in summer 
(Santos et al., 2009). The annual consumption of these drugs is not known. Seasonal 
variation in the effluent may be related to the bioactivity of microbial communities 
under different temperatures. Hong Kong and Guangdong Province are located in the 
subtropical region. Water temperature in winter is not much lower than that in 




























































































































































































































































































































































































The results obtained present the first recorded data for azithromycin, atenolol and 
simvastatin in the influents and effluents in STPs in Hong Kong and mainland China. 
The five of selected pharmaceuticals (azithromycin, erythromycin, roxithromycin, 
atenolol and simvastatin) existed at detectable concentrations in the five STPs. The 
influent and effluent concentrations of pharmaceuticals varied from plant to plant. 
Azithromycin was the highest in concentration in influents among the five 
pharmaceuticals, especially in Stonecutters Island and Guangzhou STPs. In general, 
the concentrations were in the descending order of azithromycin, atenolol, 
erythromycin, roxithromycin and simvastatin in influents. Effluent concentrations 
were in the order of azithromycin, erythromycin, roxithromycin, atenolol and 
simvastatin. Shenzhen and Guangzhou STPs had higher concentrations of 
roxithromycin and simvastatin than those in Hong Kong STPs in both influents and 
effluents. Atenolol concentrations were higher in Hong Kong STPs than the Shenzhen 
and Guangzhou STPs. 
The removal rates of atenolol and azithromycin were relatively higher than the 
other three pharmaceuticals. Dfferences were observed in the ability of the different 
types of treatment process for removing the various pharmaceuticals. 
()0 
3 EFFECTS OF PHARMACEUTICALS ON ACTIVATED SLUDGI： 
BACTERIA 
3.1 Introduction 
Emerging pharmaceuticals micropollutants are expected to be eliminated by STPs 
to a different extent. However, STPs are designed mainly for removing readily 
degradable organic compounds and nitrogen, but not pharmaceuticals that can be 
toxic to the sewage biomass. In pharmaceutical industry, this kind of wastewater 
needs the corresponding bacteria to degrade the specific drugs. Ozonation is another 
primary method to help remove drug by increasing the biodegradation effectiveness. 
The growth and nitrification activity of sludge are essential criteria for assessing the 
toxicological risk of chemicals in STPs. Growth of biomass occurs only when energy 
storage is greater than the minimum amount for energy maintenance needs (Witzig et 
al, 2002). If chemical stress caused by cytostatic drugs is put on biomass, it will lead 
to a diversion of carbon and/or energy from growth to adaptive responses and 
protection (Delgado et al., 2010). Some commonly used pharmaceuticals (ibuprofen, 
naproxen, ketoprofen, diclofenac and clofibric acid) would lead to a minor but 
consistent shift in the bacterial community structure in the bioreactor，and the key 
nitrite-oxidizing bacteria of the genus Nitrospira. were only cloned in reactors without 
pharmaceuticals (Kraigher et al., 2008). The shift of microbial population may alter 
the activity of the sludge, like reducing the nitrification capacity. Standardized growth 
and nitrification inhibition tests (ISO 15522, 1999; EN ISO 9509, 2006) have been 
established as an effective method for evaluating the toxicity of chemicals to activated 
sludge bacteria. However, there are few data on the effects of pharmaceuticals on 
wastewater treatment process and activated sludge properties. 
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Ocsircd biological conversion requires a broad bacterial composition and the 
performance of STPs largely depends on bacterial diversity (Saikaly el al., 2005). 
Therefore, instead of using a single species to assess the toxicity of pharmaceuticals, 
activated sludge were used in the tests. Halling-S0renseii (2001) found several 
broad-spectrum antibiotics like tetracycline and sulfadiazine gave EC50 in the mg/L 
range. Antibiotics with a narrower spectrum of activity like streptomycin and 
olaquindox exhibited EC50 in the |jg/L range. 
Macrolides used as broad-spectrum antibiotics inhibit protein synthesis and are 
effective against Gram-positive bacteria and most Gram-negative bacteria. Atenolol 
and simvastatin are not antibacterial agent, but (3-blocker and statin, respectively. 
Their effects on activated sludge are not known. Because of their high concentration 
in the STPs (Maurer et al., 2007; Vieno et al., 2007; Lin et al., 2009), which may 
affect wastewater treatment capacity, it is necessary to figure out their potential 
toxicity to the process of wastewater treatment. The toxicity can be observed by 
inhibition of growth and nitrification activity of the biomass. The changes in these 
two indexes reflect the ability of STPs in eliminating organic compounds such as 
antibiotics in wastewater. The inhibition tests were done according to standard test 
ISO 15522 (1999) and EN ISO 9509 (2006). 
3.2 Materials and Methods 
3.2.1 Growth inhibition test 
3.2.1.1 Preparation of biomass 
Activated sludge from the aeration tank of Shatin STP was collected and settled for 
about 15 min or longer if necessary. Fresh supernatant was used as inoculum or stored 
up to 24 h at 4"C if necessary. About 16 to 20 h before the beginning ol^  the test, 0.5 
mL supernatant per 20 mL organic test medium was added to 100 mL conical flasks 
which were placed on a shaker at about 150 r/min and incubated for 16 to 20 h in dark 
at 22 士 2 � C (Gartiser et al., 2007). This preculture ensures that there is enough 
biomass to start the main culture. Biomass was measured by turbidity (optical density, 
OD) using a spectrophotometer at 530 nm. 
Incubation cultures having sufficiently high population (i.e. turbidity > 0.6 A5 3 0 in 1 
cm optical pathlength cells) at the logarithmic phase were used as inoculum in the 
main culture. Three mL preculture was inoculated to 100 mL test medium and they 
were incubated under the condition as mentioned for the precultures. Samples were 
withdrawn at regular intervals and determined for their biomass. After 1 to 2 h of 
incubation, the main culture would reach the early exponential growth phase (i.e. 0.15 
OD5 3 0 ) and this concentration was used in the inhibition test. 
3.2.1.2 Test procedures 
A test consisted of the following samples in three replicates: five concentrations of 
reference inhibitors 3,5-dichlorophenol, macrolides and atenolol (0, 0.001, 1, 5 and 10 
mg/L), and two concentrations of simvastatin (0, 0.001 and 0.05 mg/L). Two 
concentration levels were used for simvastatin because of its low water solubility. 
Twenty mL pre-incubated main culture and 1 mL of twenty-five-fold desired 
concentrations of each pharmaceutical were added to 100 mL conical flasks and made 
up to 25 mL final volume with ultrapure water. The microorganisms were incubated 
and exposed to the pharmaceuticals under the conditions for the precultures. Total 
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incubation period should not exceed 6 h to guarantee an exponential growth of the 
bacteria during the test period. Samples were withdrawn for biomass determination at 
0, I, 2.5, 3.5, 4.5 and 5.5 h after exposure to pharmaceuticals. 
3.2.1.3 Calculation of growth inhibition 
The percentage of growth inhibition, I , at each concentration was calculated as 
follows: 
I - ( B c - B t ) / ( B c - B a ) x l O O % 
where Be is the mean value of measured OD5 3 0 at the end of the incubation period 
in the blank control flasks, Bt is the mean value of measured OD5 3 0 at the end of the 
incubation period in the test flasks, and Ba is the mean value of measured OD53 0 when 
the test material added to the flasks with the main culture. 
3.2.2 Nitrification inhibition test 
3.2.2.1 Reagents and materials 
The composition of the test medium for culturing sludge was 5.04 g/L sodium 
hydrogen carbonate (NaHCOs) and 2.65 g/L ammonium sulfate ((NH4)2S04). This 
medium contained 56 mg/L nitrogen and had a pH value of 7.6 when diluted 1:10 
with water. A^-allylthiourea (ATU, 98%) which has been reported with high 
nitrification inhibition (Aldrich, Germany) was used as the reference inhibitor. 
Solutions of test substances were prepared in water at concentrations (macrolides and 
atenolol: 0, 0.001, 0.01, 0.1 and Img/L; simvastatin: 0, 0.001, 0.005, and 0.05 mg/L), 
according to their solubility, 
3.2.2.2 Preparation of activated sludge 
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According to I he standard test method (Pagga ct uL, 2006)), nitrification is known 
to occur in activated sludge used in the test. A nitrifying activated sludge was 
collected from Shatin STP for treating predominantly domestic sewage. The sludge 
was maintained in an aerobic condition. The nitrification inhibition test was carried 
out as soon as possible and preferably within 24 h after collection, since the toxicity to 
nitrification may change during prolonged storage (Gendig et al., 2003). 
Before being used in the test, sludge was washed to remove any inhibitor and 
nitrate present. The washing procedure was carried out by settling the sludge and 
discarding the supernatant liquid. The residue was washed with a volume of tap water 
equal to the original volume and allowed to re-settle. The supernatant liquid was 
discarded again. This procedure was repeated three times and the settled sludge was 
re-suspended in an approximately volume of tap water to give the required 
concentration of mixed liquor suspended solid and aerated until use. 
The nitrifying rate was determined according to standard method (Pagga et al., 
2006). The standard test method recommends that sludge be used in the test to have 
nitrifying rates between 2 and 6.5 mg of nitrogen/ g / h of suspended solids. Sludge 
with activities outside this range may be ajusted by either dilution with water or 
concentration by settlement or centrifugation. 
3.2.2.3 Test procedures 
Test medium in the volume of 2.5 mL and 12.5 mL washed activated sludge were 
added to a series of conical flasks representing different concentrations of the 
pharmaceuticals. Then 10 mL of test solution containing target concentrations of 
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pharmaceuticals or reference inhibitor was added to llask lo make the llnal volume to 
25 mL. 
All flasks were incubated at a constant temperature of 22±2 °C in the dark for 4 h 
(or longer if the sludge activity is lower than 2 mg N/ g/ h) and aerated by shaking the 
conical flasks at such a rate to keep the sludge solids in suspension and the 
concentration of dissolved oxygen above 4 mg/L. 
At the end of incubation, 10 mL sample was taken from each vessel and the 
concentration of nitrate + nitrite determined by a Lachat QuikChem automated ion 
analyzer (AIA) using on the cadmium reduction method. 
3.2.2.4 Data analysis 
The calculation of nitrification inhibition data has been described by EN ISO 9509 
(2006). The inhibitory effect was expressed as the percentage inhibition of formation 
of oxidized N (IN , %), as follows: 
I N = ( P C -p t ) / (pc - P b ) X L 0 0 % 
where pc is the concentration of oxidized nitrogen in the control vessel without the 
test substances after incubation (mg/L); pt is the concentration of oxidized nitrogen in 
the vessel containing the test substance after incubation (mg/L); and pb is the 
concentration of oxidized nitrogen in the vessel containing the reference inhibitor 
after incubation (mg/L). 
3.3 Results and Discussion 
3.3.1 Growth inhibition of activated sludge bacteria 
% 
The relationship of biomass turbidity and bacterial density was linear in this 
experiment. Therefore, we can use value of OD 530 nm to express the bacterial 
density. Figure 3.1 shows the growth of activated sludge biomass in the presence of 
different pharmaceuticals. For sludge biomass treated with azithromycin (Figure 3.1a), 
the fastest growth was observed at 0 mg azithromycin/L from the beginning. 
Treatments with 1, 5 and 10 mg azithromycin/L inhibited the growth of sludge 
biomass. Growth rate slowed down in all treatments except the one with the lowest 
concentration, and the difference were maintained between them and 0 mg/L. At the 
end of the test, 11% growth inhibition was observed in the treatment with the lowest 
azithromycin concentration, while 80% inhibition was obtained in treatment with 10 
mg azithromycin/L (Table 3.1). Azithromycin in the settled sewage from different 
STPs could reach 950 ng/L. This concentration level is toxic to the sludge bacteria 
and may introduce resistance in some bacterial strains. The detection frequency of 
resistant bacteria increase which can also be attributed to the antibiotics found at 
increasing frequency in sewage. These put a selection pressure on bacterial strains 
which may help some strains with appropriate mechanisms of resistance to have a 
better chance of survival (Reinthaler et al., 2003). STPs that take in sewage from 
municipal sewage and hospitals show higher rate of E. coli resistance than STPs that 
only accept municipal sewage (Reinthaler et al., 2003). As high as 800 ng/L 
azithromycin in effluents may exert toxic effect on bacteria and other organisms in the 
receiving water bodies. It was repeatedly proved that resistant bacteria could be 
isolated in frequently antibiotic antibiotic-contaminated sites (Grabow et al., 1973; 
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Figure 3.1 Turbidity of biomass at a wavelength of 530 nni in the test period in 
different pharmaceuticals treatment at five concentration levels. Azithromycin (a), 
erythromycin (b), roxithromycin (c), atenolol (d) and simvastatin (e). Vertical bars are 
standard deviations (n=3). 
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‘I hero is no toxic effect of erythromycin 0.001 mg/L treatment on sludge biomass 
compared with 0 mg/L (Figure 3.1b), whereas 20%, 45% and 50% inhibition of 
growth of activated sludge were observed in 1, 5 and 10 mg/L erythromycin. However, 
Gartiser et al (2007) observed that there was no anaerobic inhibition of erythromycin 
along the whole test range (0-100 mg/L). They tested the inhibition of antibiotics by 
gas production by anaerobic bacteria. The reduction of sludge biomass would cause 
inhibition of COD removal rate and decline in STP performance because of the death 
of bacterial cells (Louvet et al., 2010a). The toxicity of erythromycin to activated 
sludge biomass was also confirmed by the microscopic image analysis of sludge floes. 
Sludge floes decreased in surface and disintegrated before disappearing (Louvet et al., 
2010a). In addition to deflocculation, there was partial biomass transfer to the scum 
layer at the surface of the liquid phase in the formation of stable foams (Alighardashi 
et al., 2009). Biomass deflocculation would affect the quality of sedimentation and 
promote the environmental release of bacteria and antibiotic resistant genes possibly 
from bacterial flora in the STPs (Louvet et al., 2010b). 
The growth curves of roxithromycin were similar to those of azithromycin (Figure 
3.1c), but with much smaller inhibitions. Growth of activated sludge was inhibited by 
21%, 50% and 54% at 1, 5 and 10 mg/L respectively. A growth inhibition of 8% was 
obtained even in the environmental concentration level of 0.001 mg/L. Growth rate 
was inhibited since the beginning of the experiment in all the macrolide treatments. 
The macrolide antibiotics showed similar pattern of the inhibition test along the test 
range. They showed a dose/response relationship at 1 and 10 mg/L treatments. This 
result showed that influents with pharmaceuticals at different concentrations had 
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ctTecls on the total biomass, but it is not possible to attribute this to spccillc toxic 
effects. Pharmaceuticals may exert effects by interfering bacteria community with 
chemical signaling and/or the initial adhesion of bacteria to surfaces. Garske et al. 
(2004) investigated that whether ceftazidime and tobramycin, as natural secondary 
metabolites, influence the development of complex microbial communities by 
interfering with chemical signaling. This is supported by the finding that the 
biosynthesis of intercellular quorum-sensing signals, involved in surface colonization 
and biofilm maturation, was influenced by antibiotics at subminimal inhibition 
concentrations. Schreiber et al (2008) studied the influence of the pharmaceuticals 
phenazone, amoxicillin and erythromycin at low, non-toxic concentrations (0.5 - 50 
l^g/L) on the initial adhesion of bacteria. The amount of initially adhered cells of 
bacteria isolated from the environment {Escherichia coli, Aquabacterium commune 
and Bacillus subtilis) was affected by the pharmaceutical compounds in a 
concentration range that included environmentally relevant level. 
Table 3.1 Growth inhibition of sludge biomass by different concentration of 
pharmaceuticals, na: growth inhibition (%) not available 
Growth inhibition (%) 
Concentration 
(mg/L) Azithromycin Erythromycin Roxithromycin Atenolol Simvastatin 
0.001 11 ± 0.7 c O l 8 ± 0.4 d 0 0 
0.05 na na na na 0 
1 54 ± 0.7 b 20 ± 0.7 c 21 ±0 .1 c 0 na 
5 79 士 0.7 a 45 士 0.7 b 50 ± 2.3 b na na 
10 80 ±2.1 a 5 0 ± l . l a 54 ±3 .8 a 0 na 
50 na na na 0 na 
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l<or atenolol and simvastatin, no eHeels were discovered in the tested 
concentration range (Figure 3.Id, e). Atenolol treatments had no inhibitory effect on 
the growth of sludge biomass, even at concentration as high as 50 mg/L (Table 3.1). 
Simvastatin concentrations were low for its slightly low water solubility (0.765 mg/L). 
Both concentrations showed no inhibition effect on sludge biomass. 
3.3.2 Inhibition of nitrifying bacteria 
The process of biological nitrogen removal, especially nitrification, may be 
susceptible to disturbance and toxic loadings (Schweighofer et al” 1996; Juliastuti et 
al” 2003; Pagga et al” 2006). Nitrifiers need high concentrations of oxygen and low 
concentrations of organic materials, and these make them more sensitive than those 
involved in denitrification. Therefore it is more important to study nitrification than 
denitrification. 
The inhibition levels increased with the concentration of macrolides (Figure 3.2). 
Macrolides treatments at 0.001 mg/L had no effect on nitrification within the test 
period. However, 0.01 and 0.1 mg/L azithromycin inhibited 22% and 37% of the 
conversion of ammonia to nitrate or nitrite, respectively. For roxithromycin and 
erythromycin, the same concentration levels had higher inhibitory effect (63% and 
68% respectively) on nitrification. At the same time, nitrifiers were more sensitive 
when compared with total bacteria community in the growth inhibition test. Although 
nitrifying bacteria were inhibited, the total biomass of sludge did not decrease to a 
corresponding extent. This suggests erythromycin and roxithromycin have high 
potency on nitrifying bacteria and/or other bacteria communities. This may result in a 
shift in the bacteria community, making unaffected species to become dominant and 
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polonlially alter the activity of sludge (Malling-S0rensen, 2001). The highest test 
concentration I mg/L of three macrolides almost completely inhibited nitrification 
(98% to 99%). Nitrification inhibition was also observed in one French STP reactor 
spiked with 10 mg/L erythromycin, but its nitrification inhibition rate was just 38% 
(Louvet et al., 2010a). However, in another French STP spiked with 10 mg/L 
erythromycin they found a -12% inhibition representing promoted nitrification 
(Louvet et al., 2010a). The presence of other pharmaceuticals in the STPs probably 
attributed to these observations, and multiple pharmaceuticals reacted to form 
compounds that stimulated nitrification. Halling-S0rensen (2001) observed an 
increase in nitrification in the presence of tylosin antibiotic. Toxicity test for another 
macrolide lincomycin was conducted on activated sludge and an inhibition effect 
(36%) was detected at 1 mg/L, although inhibition rate was lower in higher 
nitrification activity sludge (Carucci et al., 2006). 
1 0 0 � ® Azithromycin 
• Erythromycin 
一 • Roxi thromycin 丄 A ^ f c 
i 60 — -Atenolol K l • 
丨;:LjJJL 
0 0.001 0.01 0.1 1 
Concent ra t ion (mg/L) 
Figure 3.2 Inhibition of nitrification in five concentrations of macrolides and atenolol. 
Data are mean士SD of experiments (n=3). Different symbols indicate each nitrification 
inhibitions of each pharmaceutical which significantly differ from different 
concentration levels according to one-way ANOVA at P < 0.05. 
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Similar to its effect on the growth of sludge biomass, atenolol had no inhibitory 
etYect on nitrification rate (Figure 3.3). For simvastatin, no inhibition effects were 
observed at low concentrations of 0.001 and 0.005 mg/L, but at higher concentrations 
0.05 mg/L, 5% of nitrifying activity was inhibited. Carucci et al. (2006) tested 
inhibition effect of atenolol at higher concentration (40 mg/L) on the acclimated 
biomass but found no toxicity. With no acclimated biomass, toxicity effects were 
strongly affected for the nitrification activity of the activated sludge itself. If the 
sludge had low nitrification activity, atenolol showed a significant inhibition. 
However, no effect was observed when nitrification activity increased. Further study 
is needed to fully understand the effects of pharmaceuticals on the nitrogen cycle in 
STPs. 
2 0 「 
1 c： 國 Simvastatin 
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Figure 3.3 Inhibition of nitrification at the three concentrations of simvastatin. Data 
are mean士SD of experiments (n=3). 
3.4 Summary 
The most toxic compounds examined in the growth inhibition test were found to be 
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macrolides, especially azithromycin, whereas atenolol and simvastatin had no 
inhibitory effect on the growth of sludge biomass. Similar to the results of growth 
inhibition test, all atenolol and simvastatin treatments have no inhibitory effect on 
nitrification except simvastatin at 0.05 mg/L. Macrolides above 0.01 mg/L had high 
potency to nitrifiers. Although the study concentrations were higher than those 
detected in the environment (ng/L to low jug/L), the observations could be useful in 
predicting treatment performance during a shock loading of in pharmaceuticals in the 
STPs resulted from accidental discharges from hospitals or pharmaceutical factories, 
or increased antibiotic use in response to epidemics (Alighardashi et al., 2009). 
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4 BIODECRADATION PATHWAYS OF FOUR PHARMACEUTICALS 
4.1 Introduction 
111 the STP treatment process, pharmaceuticals are completely mineralized, partially 
degraded, or passed through unaltered. Since STPs provide the first, and possibly the 
only opportunity for removal of pharmaceutical residues, it is important to understand 
the possible reactions during the treatment process in the STP (Miao et al., 2005; 
Kosjek et al., 2007). The major processes of degradation (transformation) of 
pharmaceuticals are hydrolysis and enzymatic transformations during the biological 
treatment (Quintana et al,, 2005). Enzymatic reactions are often complex and may 
lead to reaction products which retain the properties of the parent compounds 
(Sunderland et al., 1999), show even greater toxicity than the parent compounds 
(Jolivette, et al., 2007), have synergistic or additive pharmacological effects in 
combination with other compounds present, or lose their pharmacological activity 
(Kosjek et al., 2007; Petrovic et al., 2007). 
Some phototransformation products of prednisone and naproxen are more persistent 
and toxic than the parent drug (DellaGreca et al., 2003 and 2004). Therefore, these 
compounds showed to be a concern, despite good removal of target compounds. 
Inherent (potential) biodegradability tests provide information regarding the 
biotreatability of a substance, and one of the most commonly applied determinations 
is the Zahn-Wellens test (ZWT) (Mascolo et al., 2010). It allows the determination of 
the extent of aerobic biodegradability of an organic compound or compound mixture 
under optimized conditions with high microbial inoculum concentration and sufficient 
oxygen (American Chemistry Council, 2007), simulating the environment of a 
chemical compound in an activated sludge treatment plant. 
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Results from ZWT are shown to be useful only for the prediction of organic carbon 
removal. However, the process of how these products are transformed or degraded is 
still a question. The metabolites or transformation products during these processes are 
unclear as well. Mass spectrometric analytical techniques provide detailed 
information of parent compounds and metabolites (Haghedooren et al., 2006). 
Through mass spectrometry, the change in pharmaceutical concentration can be 
monitored. The objectives of this part were to study the inherent biodegradability of 
pharmaceuticals and screen the possible derivatives of these four pharmaceuticals for 
further toxicity test of their by-products. The molecular weight of metabolites or 
transformation products could also be determined, and possible structure of 
derivatives speculated by MS/MS analysis. The identification of derivatives of 
pharmaceuticals could lead us to further investigate their potential effect or toxicity on 
STPs and aquatic environment. 
4.2 Materials and Methods 
4.2.1 Test procedures 
The ZWT was performed according to method described by Ramil et al. (2010). 
The activated sludge used in this experiment was collected from the Shatin STP which 
receives predominantly municipal wastewater. The sludge was washed with tap water 
three times, centrifuged and then supernatant discarded. The inoculum was 
preconditioned at room temperature and aerated until before use. The dry matter 
content of the inoculums was determined by centrifugation of known volume of 
activated sludge and drying at about 105°C to constant mass. There were three 
replicates for the test substances, two for the blank control, and one for the procedure 
control with reference compound. Atenolol concentration in the three “test’’ vessels 
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was 45 111 g/L in terms of dissolved organic carbon (DOC). Considering the toxicity of 
antibiotics to sludge bacteria, the concentrations of the three macrolides were 1 mg/L. 
With low water solubility of simvastatin (0.765 mg/L), its biodegradation pathway 
was not studied. The "procedure control" vessel contained ethylene glycol at the DOC 
concentration of 50 mg/L. The "blank" vessel only contained test medium and 
inoculums. The composition of test medium is shown in Table 4.1 (Ramil et al., 
2010). 
Table 4.1 Composition of ZWT medium (mg/L) (Ramil et al., 2010). 
Medium K H 2 P O 4 K 2 H P O 4 Na2HP04 N H 4 C I MgS04.7H20 
mg/L ^ 217.5 3M 5 ^ 
Medium CaCl2 .2H20FeCb.GHsO 
mg/L ‘ 
pH was adjusted to 7.0±0.5 with NaOH or HCl. 
The sludge concentrations were 0.2 g suspended solid/L in the final mixture. The 
final volume of the test vessel was 1 L in the 2-L vessels which were fitted with 4 mm 
inner diameter glass tubes to introduce humidified air and equipped with a magnetic 
stirrer with a 7 cm long rod. The vessels were agitated by stirrers, aerated and 
incubated at 22±2 The test lasted for 28 days. 
4.2.2 Detection method 
To eliminate the effect of sorption, 15 mL sample were withdrawn at 3 h after the 
test commenced as Day 0 samples. Degradation or transformation was monitored 
through additional 10 sampling days. The samples were centrifuged at about 40000 
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m/s' tor 15 min and stored at -20''C prior to HPLC-MS and MS/MS- analyses, while 
the DOC was measured in triplicate by a TOC analyzer (Shimadzu, Tokyo). If the 
level of DOC in the sample was under the detection limit (1 mg/L) of a total organic 
carbon (TOC) analyzer, samples were only analyzed by HPLC-MS and MS/MS. The 
m/z was valid from in/z 100 to 1000. 
Sample separation was performed by a reverse phase XBridge™ CI8 column used 
in Chapter 2. The mobile phases were 0.1% (v/v) formic acid in water (Solution A) 
and acetonitrile (Solution B) at a flow rate of 0.2 mL/min. The gradient program for 
atenolol was as follows: 5% B held for 1 min, increased linearly to 25% by 4 min and 
then to 50% by 8 min, and stepped up to 95% and held for 2 min; finally a 5-min 
equilibration step at 5% B was used. Total run time was 15 min. The gradient profiles 
of macrolide was the same as that of atenolol, accepting linear increase to 50% by 4 
min and then to 80% by 8 min. Standards and quantification methods of these four 
pharmaceuticals followed the same as decribed in the first part of the study. Data of 
mass spectra were analyzed by a Bruker data analysis system. 
For further study of possible degradation or transformation products, the samples of 
interest were analyzed by the multiple reaction monitoring scan (MRM) where only 
ion of interest entered into the collision cell and those mass fragments were detected 
by the a mass spectrometer. 
4.3 Results and Discussion 
4.3.1 Degradation of atenolol 
A significant degree of DOC elimination in the ZWT and procedure control vessels 
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were observed (Mgure 4.1). In the procedure control vessel with ethylene glycol as the 
only carbon source, 99% DOC was removed within six days. No significant DOC loss 
was found in the blank control. This indicates that the test is valid according to the 
criteria in the standard test (ISO 9888). Three vessels with atenolol, after one day lag 
phase, had about 30% DOC eliminated after four days. More than 90% DOC was 
eliminated in the 15th day. At the end of the test, DOC was reduced to below the 
detection limit. 
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Figure 4.1 DOC elimination of atenolol in the test vessels (n=3) and corresponding 
DOC in the procedure (n=2) and blank control vessels (n=2) during the ZWT. 
More details of primary biodegradation or transformation process were investigated 
by HPLC-MS and MS/MS. The total ion chromatograms (TICs) of samples were 
analyzed from Day 0 to Day 28 by data analysis software (Bruker Daltonics). At Day 
0, the TICs showed one sharp peak with a retention time of t=5.2 min and the mass 
spectrum corresponding to this peak was m/z 267.1701 [M+H]+, the protonated 
atenolol (Figure 4.2). It was confirmed by the fragment ions of atenolol, m/z 250.1436, 
225.1230, 208.0965, 190.0859, 173.0595, 162.0912 and 145.0645. According to its 
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tVagmcntalioii pattern, the possible structure was justilied (Figure 4.2). 
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Figure 4.2 Mass spectrum of atenolol in positive ESI mode and proposed 
fragmentation pathway of atenolol derived from MS^ in FT-ICR mass spectrometer. 
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I'sing the standard curve of atenolol and extracted peak area, the concentrations of 
atenolol in the test vessels can be calculated (Figure 4.3, solid line). The trend ol' 
atenolol elimination in the HPLC-MS analysis was similar to DOC measurement. 
This implies the rate of biodegradation and mineralization was close. In the early 
stage (Day 0 to Day 12), the slope of atenolol decline curve was straight. The 
degradation rate constant {k) was obtained from the slope of the linear regression line 
plotted from atenolol concentration vs. time with a high R coefficient of 0.9965 
(Figure 4.3, dashed line). It indicates that atenolol dissipation fitted the first-order 
kinetic model in that stage. The half-life times IH was 7.4 days as calculated by the 
application of this kinetic model. In the following days, the depletion of atenolol 
slowed down. Samples from Day 25 showed no atenolol peak in the HPLC 
chromatogram. At the end of test, the concentration of atenolol decreased to about 
0.03 mg/L. 
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Figure 4.3 Concentration of atenolol (solid line) and its linear regression line (dashed 
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No other obvious peaks were observed in the total HPLC chromatogram. Recent 
study by Rami I et al. (2010) showed faster disappearance time (appropriately 3 days) 
of 50% reduction of atenolol initial concentration in lab-scale water-sediment 
systems. 
With the dissipated atenolol peak {m/z 267.1701, retention time, t=5.2 min), an 
obvious new peak was shown at t=6.4 min. The intensity of this peak was increasing 
along with the depletion of atenolol peak (Figure 4.4a, b). The corresponding mass 
spectrum (Figure 4.5a) showed a peak at m/z 268.15 and a peak at m/z 134.0772 
2+ • M+2H] which was the doubly charged ions of m/z 268.154 L 
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Figure 4.4 TIC of Day 0 (a) and Day 4 (b) in ZWT samples. 
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This phenomenon occurs in the case of very strong signals, so called frequency 
fallback. To figure out the unknown product, the ion of 268.1541 was isolated and 
studied by mass spectrometry using MS/MS mode. The fragmented pattern of 
protonated molecular ion of transformation product “A” (Figure 4.5) was similar to 
protoiiated atenolol. The postulated structure of this product can be interpreted by 
amide hydrolysis from atenolol. Recent study has proved the preferred 
biotransformation pathways of amide-containing compounds to involve primary 
amides hydrolyzed rapidly; secondary amides are hydrolyzed at rates influenced by 
steric effects (Helbling et al., 2010). Only one transformation product was identified 
and amide hydrolysis was observed for atenolol. It is also consistent with previous 
findings by Radjenovic et al (2008), though the change pattern of Product A 
concentrations was quite different. In our test, the bacterial population was as high as 
0.2 g/L and Product A had already existed at the beginning of the test. Intensity kept 
increasing till Day 8, and then dropped to signal to noise ratio (S/N) under 10 on Day 
15. According to Radjenovic et al (2008), 0.05 and 10 mg/L atenolol were used in 
conventional activated sludge (CAS) and membrane bioreactor (MBR) sludge, but 
Product A reached its maximum concentration on Day 5 and remained unchanged at 
the end of the test in the CAS, but in MBR 90% disappeared. This big discrepancy 
may be attributed to the concentrations of suspended solids and composition of 
bacterial community in the biomass (Radjenovic et al., 2008). 
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Figure 4.5 Mass spectrum of the peak at a retention time t=6.4 min, which belonged 
to Product A at Day 4 sample. The peak areas as intensity are presented vs. time for 
these two compounds. 
In Figure 4.5, except peaks at m/z 268.1541 and 134.0772, a relatively low intensity 
(0.8%) peak was found at m/z 250.1431 at t=6.4 min (Figure 4.6). This unknown 
product “B，’ had the accurate mass resulted in molecular formula C14H19NO3+, which 
indicated a loss of NH3. The postulated structure of Product B is the same as 
fragmentation ion m/z 250.14 of atenolol in Figure 4.2. Product B is assumed to be 
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formed by amide hydrolysis and the loss of water to form a carbon-carbon double 
bond. The change pattern of intensity of Product B over time was similar to that of 
Product A (Figure 4.6). 
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Figure 4.6 Mass spectrum of peak at a retention time t=6.4 min belong to m/z 
250.1431. The peak areas as intensity are presented vs. time for Product B (m/z 
250.1431). 
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The change patterns these two products indicates the population of bactcria at the 
beginning of the test using atenolol for carbon source probably needed to trans form 
atenolol to Product A and/or B. This module lasted for 15 days until the bacteria were 
adapted to the only carbon source and other environmental conditions. 
From Day 15, the mass spectra did not show any peak other than a peak at m/z 
267.1701. These suggest bacteria were able to directly utilize atenolol without 
transforming to Product A and/or B. In our study, atenolol was almost completely 
mineralized which is different from the findings that atenolol was only transformed to 
a stable product but not mineralized (Radjenovic et al, 2008; Ramil et al, 2010). 
4.3.2 Degradation of azithromycin 
The removal of azithromycin in the treatment system has been investigated (Gobel 
et al., 2007; Bhandari et al., 2008; Miege et al,, 2009), but no studies have explored 
its degradation/transformation products. In the test with 1 mg/L azithromycin 
elimination reached more than 99.8%, with 0.2% (about 1300 ng/L) remaining at the 
end of experiment. In the early stage (from Day 0 to Day 12), the degradation constant 
{k) obtained from the slope of the linear regression line was higher than that in the 
later stage (from Day 12 to Day 28), which was 0.0583 and 0.0179, respectively 
(Figure 4.7). The degradation rate may be related to the concentration of azithromycin 
and the trend of degradation rate which slowed down during the test period. Under 
this optimized condition and prolonged period, azithromycin was not completely 
eliminated and remained a threat to the environment. 
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Figure 4.7 Concentration and elimination percentage of azithromycin (solid line) and 
its linear regression lines (dashed line) at the early (A) and later stage (B) in the test 
vessels. 
The intensity of azithromycin peak (Al) decreased and new peaks were shown 
from TICs of the samples in the middle and end day of the test at Days 0，12 and 28 
(Figure 4.8). A list of m/z for azithromycin and degradation/transformation products 
formed and their observed masses is shown in Table 4.2. Confirmation of these 
proposed formulae was not done because of a lack of pure compounds (proposed 
metabolites) from MS/MS detection. Regarding the proposed metabolites, a set of 
fragmentation ions were present and consistently related to the daughter spectra of 
azithromycin and previously identified azithromycin metabolites (Hunter et al,, 2003; 
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Figure 4.8 Chromatograms showing the change of prominent peaks in the 
experimental period of Day 0 (a), Day 12 (b), and Day 28 (c). Peak Al - 749.5129, 
591.4205; B- 609.4307, 767.5239; C- 607.4160, 765.5078; A2- 749.5129, 591.4205, 
829.4795, 671.3872; D- 793.4921; M- 378.2845, 394.2801; N- 376.2694; 
A3-829.4795, 671.3872; P- 610.4147, Q- 592.4047, 386.2901. 
The TIC at Day 0 shows only one single peak with a retention time of t=6.2 min, 
and mass spectrum corresponding to this peak had m/z of 749.5129 and 591.4205. The 
former was the mass of the protonated azithromycin molecular ion, while the latter 
was des-cladinose azithromycin (DCA) produced 3 h after the beginning of the test, 
which was identified as one of the fragment ions of azithromycin (Figure 4.9a). 
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Figure 4.9 Mass spectrum of azithromycin and its fragmentation ions in positive ESI 
mode and proposed fragmentation pattern derived from MS/MS. 
ESI is a soft ionization method (Veenstra et al., 1999, Harry et al., 2009) in which 
sample pressure should be low enough in the ionization chamber so that the collision 
of ions would be negligible. Therefore, m/z 591.4205 was a metabolite of 
azithromycin, rather than the fragment ion collided by ESI. It was formed by the loss 
of cladinose sugar moiety. It is known that azithromycin is converted to DCA at low 
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pi 1 by gastric degradation (Fiese et al., 1990). For our degradation test by the 
microorganisms in sludge, hydrolase may enable this reaction in moderate pH. The 
intensity of DCA was relatively high at the beginning and then slightly fluctuated until 
Day 18 (Figure 4.10a). At the last 10 days, DCA was eliminated dramatically up to 
98%. 
Along with the dissipation of azithromycin, the intensity of peaks at Day 12 
gradually increased at retention time of 5.9, 6.0 and 6.5 min (Figure 4.8). A peak at 
5.9 min had m/z 609.4307 (P609) and 767.5239 (P767). P609 was the metabolite of 
P767 by the loss of cladinose {m/z 158.0943). The proposed structure of P609 is 
shown in Figure 4.9b, which was transformed by the hydrolysis of carboxylic acid 
ester group to carboxylic acid and hydroxyl group, m/z located in the peaks at 5.9 min 
were approximately to those at 6.0 min which had m/z 607.4160 (P607) and 765.5078 
(P765). Similar to m/z 609.4307 (P609), P607 was the product of P765 by the loss of 
cladinose. P607 had two possible structures which are shown in Figure 4.9c. One was 
formed by hydroxylation (-H replaced by -OH). Another was that the third alcohol of 
P765 was transformed to ketone. The generation and elimination patterns of P607 and 
P609 were similar, and so were P765 and ？767 (Figure 4.10). P607 and P609 had 
greater intensity than P765 and P767, continuously increasing until Day 25 which 
remained high at the end of test. P765 and P767 were transformed from the beginning, 
and their intensity stayed closed to each other and dropped to below their detection 
limit. 
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Figure 4.10 Course of specific masses of transformation/biodegradation products in 
ZWT. The axis of solid line is on the left and the axis of dotted line is on the right. 
The proportion of azithromycin decreased from peak Al to A3 (retention time=6.2 
min) which was gradually dominated by m/z 671.3872 (P671) and 829.4795 (P829). 
Fragmentation studies of P829 showed product ions at m/z 671.3894, 573.4107, 
434.3122 and 416.3021. The structure of m/z 671.3894 was considerably strong which 
needed higher collision energy to produce m/z 573.4107 (which could be interpreted 
by the loss of five hydroxyl groups along with their glycosidic oxygen atoms and two 
hydrogen atoms from the aglycone ring), 434.3122 and 416.3021 (Figure 4.11). 
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According to the fragmentation pattern, it is possible that P829 was the hydroxylation 
product of azithromycin [M+50H+H]+, although the exact position of these five 
hydroxy 1 groups is not known; possible position is shown in Figure 4.11. P671 was 
also the product of P829 by the loss of cladinose (m/z 158.0943). 
The intensity of P829 was relatively high among all biodegradation (transformation) 
products and the trend of generation was similar to P671 which had lower intensity. 
They progressively increased until at high level, and slightly decreased in the middle 
of the test. They could be finally degraded or transformed, but needed a longer period. 
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Figure 4.11 Mass spectrum of P829 and proposed structure of fragmentation ion 
derived from MS/MS. 
It is hard to postulate the probable molecular formula and structure of m/z 793.4921 
(P793) at Peak D (retention=6.5 min). The fragmentation ions are shown in Figure 
1 2 5 
4.12 and m/z 671.3899 (C30H59N2O14) was the daughter ion of 1)793. Tlierdorc 1)793 
had at least 30 C, 2 N and 14 O atoms. With these criteria, software of SmartforiTiula 
(Bruker Daltonics, Germany) was used to calculate all the possible formulae with 
molecular weight difference from the theoretical mass within 10 ppm, but no formulae 
were obtained. Furthermore, m/z 749.5187 was also the daughter ion of P793 under 
higher collision energy. The structure of P793 was related to P829 and azithromycin. 
Intensity of P793 was similar to P829, which finally disappeared at the end of the test. 
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Figure 4.12 Mass spectrum of P793 and fragmentation ion derived from MS/MS. 
At the end of the test (Day 28), another three peaks were found (Figure 4.7c). A low 
intensity peak M of m/z 378.2845 (P378) and m/z 394.2801 (P394) were observed at a 
retention time of 5.5 min. P394 was probably hydroxypropyl loss 
(R-CH0HCH2CH3->R-H) from daughter ion m/z 452.3230 of P609 (Figure 4.13a). 
P378 was generated from P394 by the cleavage of -OH. These two products only 
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appeared in the last two samples and their intensities were low among ail by-products. 
Their intensities were loo low to conduct the MS/MS analysis. But the difference 
between theoretical mass and observed mass suggested that the chemical formula in 
Table 4.2 was correct. Next to Peak M, the high intensity Peak N had m/z 376.2694 
(P376) which was only shown at the last 6 days and suddenly increased to as high as 
P829. P376 was formed by dehydration o fP394 (R-CHOH-CHs-R'—R-C二CH-R'). At 
retention time=6.4 min, highest Peak P appeared with m/z 610.4147 (P610) which had 
daughter ion m/z 452.3236 (Figure 4.13d). P610 also appeared in the last two samples 
and the concentration suddenly rose. The last low intensity peak (retention time=6.6 
min) had m/z 386.2901 (P386) and 592.4047 (P592) (Figure 4.13b, c). At the earlier 
stage, the intensity of P592 was low, rose in the middle stage, and finally decreased. 
But P386 only appeared in the last two samples. 
Biodegradation of azithromycin primarily includes deconjugation of the cladinose 
sugar, hydrolysis of carboxylic acid ester group, and methyl hydroxylation in this 
simulated activated sludge treatment process. These reactions of azithromycin (Figure 
4.14) are different from those in the mammalian bodies. Mammalian 
biotransformation principally involves N-demethylation of the desosamine sugar or 
the 9a position of the macrolide ring with, to a lesser extent, O-demethylation, 
deconjugation of the cladinose sugar and hydroxylation of the desosamine or aglycone 
rings (Shepard et al., 1990; Hoepelmana et al., 1995). This suggests different 
degradation pathways in mammals and the environment. 
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Figure 4.13 Probable structures of biodegradation products and its corresponding 
daughter ions following LC/MS/MS analysis from DP610. 
The abundance of 14 biodegradation (transformation) products suggested that 
transformation dominated in the earlier stage and biodegradation intensified after 25 
days. Not a single derivative was persistent that could be classified as a microbial 
dead-end metabolite. Their microbial toxic properties are unknown. Although no test 
of antimicrobial properties of these derivatives had been conducted in this study, one 
metabolite 9a-N-desmethyl-azithromycin had been investigated and reported to have 
antimicrobial activity in python liver (Shepard et al., 1990). This does not rule out the 
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possibility that sonic of these derivatives could have antibiotic properties, cont r ibu t ing 
to the efficacy of azithromycin (Hunter et al., 2003). Further research of these 
derivatives in STP is needed. 
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Figure 4.14 Proposed structures of derivatives of azithromycin and possible 
metabolic pathways in activated sludge. 
4.3.3 Degradation of erythromycin 
The elimination rate of erythromycin was slow in the early test period and then 
dramatically increased from Day 18. It increased from 35% to 77% between one 
sampling intervals. Similar to azithromycin, most of the erythromycin were mostly 
removed at the end, but the remaining antibiotic was still high for the environment. 
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Erythromycin molecular ion {m/z 734.4698) dissociated predominantly to ions at 
ni/z 576.3754, 716.4597, 558.3660, 522.3440, 698.4553 and 540.3662. High relatively 
abundance was at w/z 576.3754 formed by the loss of cladinose, [M+H-158]^ (Figure 
4.15). The consecutive losses of water from erythromycin led to m/z 716.4597 and 
698.4553. Loss of the cladinose residue and water molecules led to the formation of 
ions at m/z 558.3660, 540.3662 and 522.3440, respectively. 
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Figure 4.15 MS/MS spectrum and elimination percentage of erythromycin in the test 
vessels. 
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An interesting phenomenon was observed that the intensity of all derivatives 
decreased. The decreasing patterns of the derivatives appeared at the first day of the 
test were similar to that of erythromycin which suddenly declined to low intensity 
(Figure 4.16). 
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Figure 4.16 TICs showing the change of peaks in the experimental period of Day 0 (a), 
Day 18(b), Day 22 (c) and Day 28(d). 
The TICs at Day 0 and Day 18 were very different from those at Day 22 and Day 
28. There were no new peaks between Day 0 and 18. Apart from two derivatives m/z 
720.4560 (P720) and 748.4477 (P748), structures of the other four were as mentioned 
before. Figure 4.17 shows the fragmentation ion of P720, including m/z 522.3440, 
540.3527, 558.3660 and 576.3754. P720 was generated by 2 ‘ -demethylation of 
cladinose ring. P748 was found in the literature as transformed product of 
erythromycin (Haghedooren et al., 2006). The research of biodegradation product of 
erythromycin in STP is rare; most focused in the mammalian body (Kim et al., 2004; 
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I lassanzadch ct "/•’ 2007). The causc of change patterns of erythromycin and its 
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Figure 4.17 Course of specific masses of derivatives of erythromycin in ZWT, 
MS/MS spectrum of P720 and structure of P748. 
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4.3.4 Degradation of roxithromycin 
Protonated molecular ion roxithromycin {m/z 837.5379) was eluted at retention 
time of 7.6 min. Its structure was stable, to having only one daughter ion m/z 
679.4403 formed by the loss of 
4-methoxy-4,6-dimethyl-tetrahydropyran-2,5-diol(cladinose moiety), even under 20v 
collision energy (Figure 4.18a). No significant changes in roxithromycin 
concentration were found in the ZWT (Figure 4.18b). In the control vessel with 
ethylene glycol as the only carbon source, 99% DOC was removed within 6 days. 
This indicates the microorganisms in the sludge used in the test were viable and 
effective. 
The persistence of roxithromycin was reported in previous investigations. Li et al. 
(2010) found no roxithromycin biodegradation occurred and was removed mainly via 
adsorption in STP treatment. Only in ozonation batch experiment，roxithromycin was 
oxidized in the reaction involving .OH radical (Radjenovic et al., 2009). The 
persistence of roxithromycin showed that it is non-biodegradable even in an aerobic 
environment with high microbial diversity and oxygen concentration. The 
determination of wastewater samples in Chapter 2 showed high roxithromycin 
concentrations in influent (800 ng/L) and effluent (400 ng/L) from STPs in the 
Guangdong Province, The measurement of environmental samples for roxithromycin 
and its potential effects are needed. 
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Figure 4.18 Fragmentation pattern of roxithromycin in MS/MS spectrum (a) and 
concentration of atenolol protonated molecular ion (m/z 837.5379) (b). 
4.4 Summary 
The degradation of four pharmaceuticals was investigated to determine their 
derivatives in the STP process. Characterization of degradation products was carried 
out by MS/MS and the pathways of decomposition were proposed. Atenolol was 
found to be degraded rapidly and no molecular ions were detected at the end of the 
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test. Azithromycin had several derivatives, some of which were still at high 
concentration if discharged to the environment. Erythromycin was degraded slowly 
before Day 18 and then it and its derivatives dramatically decreased in a short time. 
No degradation of roxithromycin was found in the whole test. These help belter 
understanding of the degradation pathways of the four pharmaceuticals. Atenolol 
could be almost completely mineralized. Many derivatives of azithromycin were 
observed, some of which had similar structure of their parent compound. They should 
be included in future toxicity studies. Similar elimination pattern of erythromycin and 
its derivatives indicates that erythromycin was transformed to its derivatives by 
microorganisms and then degraded to simpler compounds. The abrupted degradation 
is hard to explain and further investigation is needed. The nonbiodegradable 
roxithromycin were active for a prolonged period and investigation of its aquatic 
toxicity is needed. 
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5 GENERAL CONCLUSIONS 
Pharmaceuticals have been the focus of many researches concerning their 
occurrence and fate in the aquatic environment over the last twenty years. Some of 
them have been reported in sewage, river, drinking water and groundwater. The 
effluent of STPs has been considered as an important source of pollution and was 
selected for study in this thesis. 
In the first part，the occurrence of the five target pharmaceuticals (azithromycin, 
erythromycin, roxithromycin, atenolol and simvastatin) with potential toxic effects 
and high consumption in the region was studied. The combination of solid phase 
extraction and LCMS enabled the trace level detection of these pharmaceuticals in 
wastewater samples. The presence of azithromycin and simvastatin were first reported 
in sewage samples. All these pharmaceuticals were detected in the five study STPs. 
The concentrations were in the range of 200-1200 ng/L in influents and 100-500 ng/L 
in effluents of STPs. Concentrations of macrolides and simvastatin were higher in 
STPs in the Guangdong Province than in Hong Kong. However, the situation of 
atenolol was opposite, indicating that atenolol was highly consumed in Hong Kong. 
Overuse of antibiotics is a common phenomenon in mainland China that plays a key 
role on the contribution to their abundance in the influents and effluents of STPs. 
Their fates in STPs depend on their properties and the performance of the unit process. 
In this research, the removal efficiencies of different pharmaceuticals varied. In 
general, treatment process: adsorption-biodegradation (oxidation ditch) and A^/0 
process had higher removal performance. The removal rates of atenolol and 
azithromycin (approximately 30-60%) were relatively higher than the other three 
pharmaceuticals (approximately 12-45%). From the 6-month sampling, seasonal 
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variation in removal efficiency was not obvious. 
In the second part, their toxicological risk in STPs was assessed by the growth rate 
and nitrification activity of sludge. Following the standard tests of ISO, macrolides 
were proved to have inhibition effect on sludge. In particular, azithromycin was 
observed to inhibit as high as 80% biomass growth rate of sludge. All three 
macrolides completely inhibited nitrification activity when their concentrations were 
1 mg/L. However, atenolol and simvastatin were observed to have no inhibitory 
effects. 
Besides the parent compounds of these pharmaceuticals, their metabolites or 
transformation products could be potentially toxic to aquatic organisms. 
Biodegradation test of three macrolides and atenolol were conducted, simulating the 
environment of a chemical compound in an activated sludge treatment plant. Some 
derivatives were observed in the test of atenolol, azithromycin and erythromycin. 
Roxithromycin could be classified as a persistent compound. No new molecule 
masses were observed. From the degradation of the three macrolides which had 
similar structure, the derivates and elimination rate could be very different. The 
degradation pathway and derivatives of pharmaceuticals from the same group have to 
be studied separately. Information obtained would help environmental sample 
measurement and toxicity test for the isolation of the toxic derivatives. 
This is the first study that reported the occurrence of azithromycin and simvastatin 
in STPs of Hong Kong and the Guangdong Province. Data on the concentrations of 
the five pharmaceuticals in the effluent allow us to understand the pollution that may 
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be introduced to aquatic environment. From the two inhibition tests, we know the 
influence of these pharmaceuticals on the sludge and their levels that would be toxic 
to microorganisms. Furthermore, the study of biodegradation helps us find out the 
lifetime of these pharmaceuticals in the optimized condition and provides information 
for toxicity assessment. 
The effects of pharmaceuticals on the environment are not clear and further 
research is required to elucidate the long-term chronic impact of their environmental 
concentrations on the natural ecosystem and human health. The reduction at source 
will be an effective way to solve the pollution problem. We have to develop and 
produce drugs which are more environmentally friendly and biodegradable but less 
ecotoxic. Reducing excessive consumption of antibiotics and improper disposal are 
beneficial ways to protect our ecosystems and human health. 
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